Identification of downstream genes of the TRPS1 transcription factor by Brega, Paola
 Institute of Human Genetics 
University Duisburg-Essen 
 
 
 
 
Identification of downstream genes 
of the TRPS1 transcription factor 
 
 
 
 
Inaugural Dissertation 
 
 
 
 
 
to obtain the degree of 
Dr. rer. nat. 
Fachbereich Bio- und Geowissenschaften 
at the 
University Duisburg-Essen 
 
 
 
 
 
 
 
 by 
 
Paola Brega 
 
from Genf 
 
June 2005 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die der vorliegenden Arbeit zugrundeliegenden Experimente wurden  
am Institut für Humangenetik der Universität-Duisburg-Essen  
durchgeführt. 
1. Gutachter: Prof. Dr. B. Horsthemke 
2. Gutachter: Prof. Dr. H. Esche 
Vorsitzender des Prüfungsausschusses: Prof. Dr. R. Küppers 
Tag der mündlichen Prüfung: 23. Juni 2005 
 
  
  
PUBLICATION 
 
 
Kaiser F.J., Brega P., Raff M.L., Byers P.H., Gallati S., Taylor Kay T.,  
de Almeida S., Horsthemke B. and Lüdecke H.-J. (2004) Novel 
missense mutations in the TRPS1 transcription factor define the 
nuclear localization signal. Eur J Hum Gen 12: 121-126 
 
 CONTENTS 
 
 
1. INTRODUCTION                                                                   1 
 
1.1      Skeletal defects in the tricho-rhino-phalangeal syndrome           1      
1.2      Endochondral bone formation and chondrocyte differentiation     1        
1.2.1   Extracellular matrix in skeletal development          3 
1.3       Tricho-rhino-phalangeal syndromes and the TRPS1 gene   4   
1.4       The TRPS1 transcription factor                                                 7   
1.5      Correlation between Trps1 in development and disease              9      
1.6      Deletion of the GATA-type zinc finger in Trps1 provides new 
      insight into the TRPS bone disorders      10   
 
1.7       Aims                   11 
       
 
 
2.     MATERIALS AND METHODS            12 
 
2.1      Materials                             12 
 
2.1.1       Chemicals           12 
2.1.2  Standard solutions and mediums               12 
2.1.3       DNA and proteins markers      12 
2.1.4          Restriction enzymes                  13 
2.1.5       Bacterial plasmids         13 
2.1.6        Trps1 knockout mice                         13 
 
2.2      Methods                          14 
 
2.2.1        Nucleic acid purification        14 
2.2.1.1 DNA isolation from cells                         14 
2.2.1.2 RNA isolation from animal cells and tissues                          14 
2.2.1.2.1       DNase treatment of the RNA                                                  15                      
2.2.2  Polymerase Chain Reaction (PCR)      15 
2.2.3  Reverse-Transcriptase Polymerase Chain Reaction  
(RT-PCR)             16 
2.2.4   In vitro site-directed mutagenesis                                           16 
2.2.5             Restriction analysis                                                                17 
2.2.6             Agarose gel electrophoresis                                                    17 
2.2.7  Purification of DNA fragments                                        17 
2.2.7.1 Purification of PCR products                                              17 
2.2.7.2 Purification of restriction products                                    18 
2.2.7.3 Gel slice extraction                                                   18 
2.2.8  Ligation                                                                  18 
2.2.9  Bacterial transformation       19 
2.2.9.1 Bacteria strain       19 
2.2.9.2 Transformation of competent bacteria    19 
2.2.10           Plasmid DNA isolation      19 
2.2.10.1        Small-scale analytic preparation of plasmid DNA    19 
2.2.10.2      Large-scale preparation of plasmid DNA      20 
2.2.11 Quantification of nucleic acids concentration     20 
2.2.12 Sequencing         21 
2.2.13 Microarray analysis        21 
2.2.14   Real-time PCR       22 
I
  
  
2.2.15 Mutation analysis of the TRPS1 gene               22 
2.2.16 Cell culture         23 
2.2.16.1 Cell lines         23 
2.2.16.2 Cell cultures medium       23 
2.2.16.3         Growth and maintenance of live cell cultures    23 
2.2.17  Luciferase reporter gene assay      24 
2.2.18   Proteins         24 
2.2.18.1  Total cell protein extract       24 
2.2.18.2         Quantification of proteins in solution     25 
2.2.18.3         Discontinous SDS polyacrylamide 
 gel electrophoresis  (SDS-PAGE)     25 
2.2.18.4  Western-blot and protein detection     26 
2.2.19            RNA interference        27 
2.2.20   TRPS1 transgenic mice       28 
2.2.20.1  In situ hybridization       28 
2.2.20.2  Safranin staining         29 
2.2.20.3  Mouse skeletal preparation      30 
     
 
 
3.      RESULTS              31 
 
3.1  Mutation analyses        31 
3.2  RNA interference and microarray analysis    32 
3.2.1  Trps1 silencing in NIH3T3 cells      33 
3.2.2  cDNA microarray analysis       34 
3.3  Generation and characterization of TRPS1 transgenic mice  38 
3.3.1  Generation of transgenic mice      38 
3.3.2  Assessment of transgene expression     41 
3.3.3  Gross phenotype and skeletal morphology    42 
3.3.4  In situ hybridization        44 
3.4    cDNA microarray analysis of mouse embryonic tissues   48 
3.4.1  cDNA microarray analysis of mouse embryonic limbs   48 
3.4.1.1          The relative expression of several genes was       
confirmed by real-time PCR experiments     52 
3.4.1.2          TRPS1 actively represses the HSPG2 promoter activity   55 
3.4.2             cDNA microarray analysis of mouse embryonic snouts  57 
3.4.2.1          The relative expression of three genes was confirmed 
by real-time PCR experiments      64 
3.4.2.2          TPRS1 actively represses the LAPTM4b promoter activity  66 
   
 
 
4.      DISCUSSION        68 
 
4.1            TRPS1 carries a single functional NLS      68 
4.2  The TRPS1 transgenic mouse does not  
                     represent a model for TRPS III      68 
4.3  Identification of the downstream genes of                                   
                    the TRPS1 transcription factor      70 
4.3.1            The silencing of the Trps1 transcription factor in NIH3T3 might      
interfere with the control of cell cycle progression   70 
4.3.2             Microarray analysis of GATA Znf-deleted                             
Trps1 mouse embryonic tissues     73 
4.3.2.1  Downstream genes of Trps1 in embryonic limbs    75 
4.3.2.2 Downstream genes of Trps1 in embryonic snouts   78 
 
II
  
  
4.3.2.3          Laptm4b is the only gene upregulated in both     
Trps1+/∆GATA-Znf and in Trps1∆GATA-Znf/∆GATA-Znf mice,  
in embryonic limbs and snouts       79 
4.3.2.4          TRPS1 directly represses HSPG2 promoter activity   81  
4.3.2.5          Is Hspg2 overexpression in the growth plate         
                    responsible for disturbed cell-matrix interaction  
in the chondrocytes of TRPS patients?      83 
4.3.2.6          Does HSPG2 overexpression contribute to the                    
                    onset of osteoarthritis in TRPS patients?      84 
 
 
5.  ABSTRACT       85 
 
 
6.   APPENDIX        86 
 
 
7.  LITERATURE       88 
 
 
Danksagung/Ringraziamenti             98 
 
CURRICULUM VITAE                                                             99 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
  
  
IMPORTANT ABBREVIATIONS 
 
aa  amino acid 
BM  basement membrane 
bp  base pairs 
BSA  bovine serum albumine 
cDNA  complementary DNA 
Ci  Curies 
CSEs  cone-shaped epiphyses 
DNA  deoxyribonucleic acid 
ECM  extracellular matrix 
min  minutes 
mRNA  messenger RNA 
NLS  nuclear localization signal 
nt  nucleotide 
O/N  overnight 
ORF  open reading frame 
RNA  ribonucleic acid 
RNAi  RNA interference 
RT  room temperature 
sec  seconds 
siRNA  small interfering RNAs 
TRPS  tricho-rhino-phalangeal syndrome 
Znf  zinc finger 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV
  
 1
Introduction 
1  INTRODUCTION 
 
1.1  Skeletal defects in the tricho-rhino-phalangeal syndrome 
 
The tricho-rhino-phalangeal syndrome (TRPS) is an autosomal dominant 
inherited disease characterized by craniofacial and skeletal defects (Giedion, 
1966). The skeletal defects, which include cone-shaped epiphyses of the 
phalanges, varying degrees of brachydactyly and short stature, are probably 
due to an impaired maturation of chondrocytes in the growth plate of many 
tubular bones (Lüdecke et al., 2001). 
 
 
1.2   Endochondral bone formation and chondrocyte 
differentiation 
 
Bone formation begins when mesenchymal cells form condensations, clusters 
of cells that adhere through the expression of adhesion molecules (review: 
Olsen et al., 2000). In a few areas, like the flat bones of the skull, the cells of 
these condensations differentiate directly into bone-forming osteoblasts in a 
process called intramembranous bone formation.  
Most condensations of the axial and appendicular skeleton, for example in 
the limbs, where extensive growth is required for proximal-distal extension of 
the long bones, form a cartilage template, which is then replaced by bone in 
the process of endochondral bone formation. At the beginning of this 
process, the condensed cells become chondrocytes, the primary cell type of 
the cartilage. The cells at the border of condensations form a perichondrium. 
Chondrocytes have a characteristic shape and they secrete a matrix rich in 
type II collagen and the proteoglycan aggrecan. More generally, 
chondrocytes express a characteristic genetic program driven by different 
transcription factors, like SOX9, essential for converting cells of 
condensations into chondrocytes (Bi et al., 1999) and CBFA1/RUNX2, master 
regulator of osteoblast differentiation (Otto et al., 1997; Komori et al., 
1997). Mutations in SOX9 cause the rare and severe dwarfism campomelic 
dysplasia (CD) (Foster et al., 1994; Wagner et al., 1994) whereas 
haploinsufficiency of CBFA1/RUNX2 causes cleidocranial dysplasia (CCD) 
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(Mundlos et al., 1997). The cartilage enlarges through proliferation of 
chondrocytes and perichondrial cells, as well as through deposition of new 
matrix. At a certain stage, specific for each skeletal element, cells in the 
center undergo further maturation into hypertrophic chondrocytes by 
stopping proliferation, enlargement and secretion of a new matrix composed 
uniquely by type X collagen that becomes progressively calcified. Changes in 
the composition and properties of the cartilage matrix in the hypertrophic 
zone allow invasion by capillaries and secretion of angiogenic factors, 
accompanied by apoptosis of terminally differentiated chondrocytes and 
replacement of the calcified cartilage matrix by the trabecular bone matrix 
secreted by invading osteoblasts. This results in the formation of primary 
ossification centers. At the same time, osteoblasts in the perichondrium form 
a collar of compact bone around the middle portion (diaphysis) of the 
cartilage, so that the primary ossification center ends up being located inside 
a tube of bone. At one or both ends (epiphyses) of the cartilage, secondary 
ossification centers are formed, leaving a plate of cartilage, called growth 
plate between epiphysis and diaphysis. In the growth plate, a coordinated 
sequence of chondrocyte proliferation, hypertrophy, and apoptosis results in 
longitudinal growth of bones. At the same time, these processes are 
coordinated with growth of the epiphysis and radial growth of the diaphysis. 
 
Several complex signaling pathways control bone growth (review: 
Kronenberg, 2003). One of this is the Ihh/PTHrP signaling (Vortkamp et al., 
1996; Lanske et al., 1996).  
Indian hedgehog (Ihh), expressed by post mitotic cells in the prehypertrophic 
zone of growth plate cartilage, has several roles in regulating longitudinal 
bone growth. By signaling through Patched/Smoothened, Ihh controls bone 
formation in the bone collar and proliferation of chondrocytes in the 
proliferative growth plate zone by mechanisms that are independent of 
parathyroid hormone related protein (PTHrP) and it maintains the pool of 
proliferative chondrocytes in the growth plate through stimulation of PTHrP 
synthesis in the periarticular perichondrium. Increased signaling through the 
PTHrP receptor causes delay of chondrocyte hypertrophy and associated 
expression of Ihh, collagen X and vascular endothelial growth factor (VEGF), 
and expansion of the pool of proliferating cells (Schipani et al., 1997); 
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decreased signaling has the opposite effect (reviews: Wallis, 1996; Olsen et 
al., 2000).  
Other signaling pathways involve the fibroblast growth factors (FGFs) 
(review: Ornitz and Marie, 2002) and the bone morphogenetic proteins 
(BMPs) (Minina et al., 2002). These locally produced factors are joined by 
systemic factors such as growth hormone, thyroid hormone, estrogen, 
androgen, vitamin D, and glucocorticoids to control bone growth (review: 
Van der Eerden et al., 2003). 
 
 
1.2.1  Extracellular matrix in skeletal development 
 
The extracellular matrix (ECM), a complex structural entity surrounding and 
supporting cells, is found within mammalian tissues. ECM is composed of 
three major classes of biomolecules: (a) structural proteins like collagen and 
elastin, (b) specialized proteins like fibrillin, fibronectin, and laminin, (c) 
proteoglycans, which are composed of a protein core to which long chains of 
repeating disaccharide units termed of glycosaminoglycans (GAGs) are 
attached forming extremely complex high molecular weight components of 
the ECM. Extracellular matrix components of cartilage and bone have critical 
roles in skeletal development as demonstrated by the large number of 
skeletal dysplasia caused by mutations in matrix molecules.  
Heterozygous mutations in COL1A1 and COL1A2, the genes coding for the 
α1(I) and α2(I) chains of collagen type I, respectively, cause osteogenesis 
imperfecta (OI) (Kocher and Shapiro, 1998), which is a heterogeneous group 
of skeletal disorders characterized by brittle bones, hearing loss, blue 
sclerae, and dentinogenesis imperfecta.  
Type II collagen, a homotrimer encoded by COL2A1, is the major structural 
collagen component of the cartilage, vitrous of the eye, the nucleus pulposus 
of intervertebral discs, and the tectorial membrane of the ear. Mutations in 
type II collagen cause a spectrum of diseases known as type II 
collagenopathies, whose severity ranges from lethality (achondrogenesis type 
II, hypochondrogenesis) to severe dwarfism (spondyloepiphyseal dysplasia 
congenita, Kniest dysplasia), as well as normal stature with early-onset 
osteoarthritis (Stickler syndrome and others) (Spranger et al., 1994).  
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Type X collagen, a member of the short chain collagen family, is a 
homotrimeric molecule expressed by hypertrophic chondrocytes during 
endochondral ossification. In humans, mutations in COL10A1 have been 
shown to cause the autosomal dominant disorder Schmid metaphyseal 
chondrodysplasia, which is characterized by bowing of the legs, growth 
retardation of the lower extremities, and coxa vara (Warman et al., 1993).  
The major proteoglycan in cartilage, aggrecan, contains a core protein that is 
modified by substitution of chondroitin and keratan sulfate chains and other 
oligosaccharides. Mice with the aggrecan frameshift mutation, called cartilage 
matrix deficiency (cmd), have short limbs, tails and snouts, cleft palate, and 
intervertebral disc abnormalities (Watanabe et al., 1997).  
Loss-of-function mutations in the major heparane sulfate proteoglycan in 
cartilage, perlecan, cause the Schwartz-Jampel syndrome which is a unique 
combination of myotonia and chondrodysplasia (Nicole et al., 2000).  
 
 
1.3 Tricho-rhino-phalangeal syndromes and the TRPS1 gene 
 
Giedion (1966) first described the autosomal dominantly inherited tricho-
rhino-phalangeal syndrome (TRPS). Major features are sparse, slowly 
growing scalp hair, laterally sparse eyebrows, a bulbous tip of the nose, and 
protruding ears. Highly characteristic are the long flat philtrum and the thin 
upper vermillion border (Fig. 1A). The most typical radiographic findings in 
TRPS are cone-shaped epiphyses (CSEs) (Fig. 1B), predominantly at the 
middle phalanges. Often, they are not detectable before two years of age 
(Giedion, 1998).  CSEs and premature closure of the growth plates can also 
be found at other tubular bones, however, with a much lower incidence 
(Giedion, 1968). The skeletal age always lags behind the chronological age 
until puberty and then typical accelerates. Hip malformations are present in 
>70% of patients.  
Langer (1969) described a thoraco-pelvic-phalangeal dystrophy that shared 
several symptoms with the TRPS, but in addition, the patients also had 
mental retardation, microcephaly and multiple cartilaginous exostoses (EXT). 
This disorder was termed TRPS type II (MIM 150230), whereas the originally 
described was designated TRPS type I (MIM 190350). In 1980, Bühler et al. 
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described the first report of an 8q deletion in a TRPS II patient and four years 
later, thanks to a clinical and cytogenetic review of 17 patients, the shortest 
region of overlap of the 8q deletion in TRPS II patients was defined at band 
8q24.1 (Bühler and Malik, 1984).   
 
Sugio and Kajii (1984) and Niikawa and Kamei (1986) described mentally 
normal patients with the typical facial appearance of TRPS I but with more 
severe brachydactyly and growth retardation. None of the patients has 
multiple exostoses. Niikawa and Kamei (1986) proposed the diagnosis of 
TRPS III (MIM 190351) for these patients. Since then, a few more patients 
have been described (Nagai et al., 1994; Itin et al., 1996; Vilain et al., 1999; 
Lüdecke et al., 2001; Kobayashi et al., 2002; Hilton et al., 2002). 
An apparently balanced chromosome (8;18) translocation involving 8q24.11 
in a family with two sibs with TRPS type I (Marchau et al., 1993) facilitated 
the narrowing down of the TRPS1 gene proximal to the EXT1 gene (Lüdecke 
et al., 1995).  
 
Fig. 1 A, Female patient who shows the typical craniofacial features of the TRPS type 
I. B, X-rays showing hands of a patient with TRPS type I. Note the characteristic 
cone-shaped epiphyses. 
 
 
Recently the human TRPS1 gene has been identified (MIM 604386, 
AF178030, AF183810) (Momeni et al., 2000) (Fig. 2A). It is composed of 
seven exons and spans 260500 bp of genomic DNA. The open reading frame 
A                                                      B
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(ORF) is 3843 bp and starts at the third nucleotide of exon 3. The mouse 
Trps1 gene has been also isolated and characterized (Momeni, 2001) (Fig. 
2B). It is composed of six exons, because it has no equivalent to the non-
coding human exon 2. The mouse Trps1 ORF sequence shows 91.3% identity 
with the human TRPS1 sequence. The two proteins display 93.1% identity in 
their amino acid sequences. 
 
 
 
 
Fig.2 Comparison between the human TRPS1 (A) and the mouse Trps1 (B) gene. 
The open boxes represent the exons. The start and stop codons are indicated. The 
blue hatched boxes represent the zinc fingers motifs and the yellow hatched box 
represents the nuclear localization signal (NLS) (see section 1.4). 
 
 
Point mutations, deletions of one complete TRPS1 allele, translocations and 
inversions in the TRPS1 gene are responsible for TRPS type I and type III 
(Hatamura et al., 2001; Lüdecke et al. 2001; Seitz et al., 2001; Hilton et al., 
2002; Gentile et al., 2003; Kaiser et al, 2004). The deletion of both TRPS1 
and EXT1 leads to TRPS II. 
Independently, TRPS1 was cloned and described by Chang et al. (2000), 
named as GC79, studying androgen-dependent LNCaP-FGC human prostate 
 1 2    3         4     5  6       7                     
 1      2         3      4 5       6 
 
A TRPS1 
B Trps1 
ATG 
ATG TAA 
TAA 
1 kb 
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cancer cells, where TRPS1 is higher expressed when compared with 
androgen-independent LNCaP-LNO human prostate cancer cells. 
 
 
1.4   The TRPS1 transcription factor  
 
The TRPS1 gene encodes the 1281 amino acids nuclear transcription factor 
TRPS1 (Fig. 3) with an unusual combination of nine zinc finger (Znf) motifs 
(Momeni et al., 2000). The function of the first six Znfs has not yet been 
determined. The seventh is a GATA-like Znf and it is able to bind to the GATA 
consensus sequence (Malik et al., 2001). So far, six members of the GATA 
family of transcription factors have been identified in vertebrates and each of 
them contains a highly conserved DNA binding domain consisting of two 
Znfs. The C-terminal Znf domain is essential for recognition and binding to 
(A/T)GATA(A/G) motifs, whereas the N-terminal  Znf domain contributes to 
this interaction by influencing the specificity and stability of the DNA binding 
(Molkentin, 2000; Trainor et al., 2000; Trainor et al., 1996). The presence of 
only a single GATA Znf, as in TRPS1, is only common in invertebrates like 
fungi, plants, nematodes and insects (Daniel-Vedele and Caboche, 1993).  In 
vertebrates, only two other cases of single GATA Znf proteins are known. 
One protein is the so-called TSGA, which is a testis-specific putative 
transcription factor (Höög et al., 1991); the other protein is encoded by the 
hairless gene (Cachon-Gonzales et al., 1994). 
The two most C-terminal Znfs (the eighth and the ninth) of TRPS1 exhibit a 
high similarity to the C-terminal double Znfs of the IKAROS family of 
lymphoid transcription factors, which are necessary for dimerization between 
IKAROS proteins and other family members (Sun et al., 1996; McCarthy et 
al., 2003). TRPS1 carries a single nuclear localization signal (NLS) (Kaiser et 
al., 2004). So far, TRPS1 is the only vertebrate and invertebrate recognized 
transcription factor that contains both GATA- and Ikaros-like Znfs. 
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Fig. 3 Predicted structure of the TRPS1 protein. NLS: nuclear localization signal  
Znf: zinc finger 
 
Genotype-phenotype correlation studies (Lüdecke et al., 2001) indicated that 
missense mutations in the GATA zinc finger of TRPS1 are associated with the 
severe TRPS type III phenotype. This is probably due to a dominant negative 
effect exerted by the mutant proteins with an altered GATA zinc finger, which 
have a decreased affinity to DNA but are still able to bind the co-factors of 
the involved protein complexes. In contrast, TRPS type I is correlated with 
nonsense mutations, deletions of one complete allele, and with the other two 
missense mutations, found in the NLS of TRPS1 (Kaiser et al., 2004). In this 
case, the disease is probably due to a reduction of the TRPS1 concentration 
in the nucleus, a phenomenon called haploinsufficiency (Seidman and 
Seidman, 2002). 
 
Several functional analyses of this interesting and unusual transcription 
factor have been carried out in the last years.  
Chang et al. (2000) observed that physiological levels of androgens 
repressed the expression of TRPS1/GC79 mRNA in LNCaP-FGC (androgen-
dependent human prostate cancer cells). Castration-induced androgen 
withdrawal in rat ventral prostate, used to induce apoptosis in the prostate, 
increased the expression of GC79 mRNA leading to the hypothesis that 
TRPS1/GC79 can be implicated in the process of apoptotic cell death in the 
rat ventrale prostate.  
Malik et al. (2001) have shown that TRPS1 represses GATA-mediated gene 
activation and that its transcription repressional function is dependent on the 
presence of both the GATA- and the Ikaros-like Znfs.  
Recently, two binding partners of the TRPS1 transcription factor have been 
identified. Kaiser et al. (2003a) reported that the nuclear interaction of the 
dynein light chain LC8a with TRPS1 suppressed the transcriptional repression 
NLS 
100 aa 
             GATA-like     
             zinc finger  
 
Ikaros-like 
zinc fingers                  Znf1  Znf2   Znf3     Znf4 Znf5 Znf6 
N C 
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activity of TRPS1. The interaction of the RING finger protein RNF4 with 
TRPS1 was able to inhibit the repressional function of TRPS1 (Kaiser et al., 
2003b).  
 
Target genes of TRPS1 have not yet been identified. Thus, the signaling 
pathways in which TRPS1 acts, for example during endochondral ossification, 
are still unknown. 
 
 
1.5  Correlation between Trps1 in development and disease 
 
In order to get insight into the important function of Trps1 during mouse 
embryonic development, Kunath et al. (2002) performed whole-mount in situ 
hybridization of embryonic stage 10.5 (E10.5)-E14.5 mouse embryos with a 
Trps1 antisense probe (Fig. 4). They showed that strong Trps1 expression is 
found in the cartilage condensations, the hair follicles and in the developing 
snout, strongly suggesting that the main features of TRPS probably are the 
consequences of defects already occurring during embryonic stages. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Whole-mount in situ hybridization (performed by Kunath et al., 2002) of 
E10.5 (A), E11.5 (B), E12.5 (C) and E14.5 (D) mouse embryos with a Trps1 
antisense probe. FL: forelimbs. HL: hindlimbs. P: pharyngeal arches. Arrowheads 
demarcate hair follicles. 
 
 
Kunath et al., 2002 
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By in situ hybridization performed on tissue sections, Kunath et al. (2002) 
showed that, in the developing skeletal elements of E14.5 limbs, Trps1 is 
expressed in the joint regions, in the periarticular and in the prehypertrophic 
chondrocytes (data not shown). 
 
 
1.6  Deletion of the GATA-type zinc finger in Trps1 provides 
new insight into the TRPS bone disorders 
 
Lüdecke et al. (2001) described a mutation (IVS6+1G>T) in the splice-donor 
site of intron 6 of the TRPS1 resulting in frame skipping of exon 6 and thus in 
the deletion of the entire GATA-Znf coding domain. This mutation led to a 
TRPS I phenotype in a female patient. 
 
Malik et al. (2002) generated Trps1 knockout mice, which lacks the mouse 
exon 5 (equivalent to human exon 6) and thus resembling the state present 
in the patient with the site splice mutation. The mutant allele, which does not 
contain the GATA-Znf coding domain (∆GATA-Znf), is expressed in both 
Trps1+/∆GATA-Znf and Trps1∆GATA-Znf/∆GATA-Znf mice. The authors reported that 
Trps1+/∆GATA-Znf mice with deletions of the TRPS1 GATA Znf domain displayed 
facial anomalies that overlapped with findings for TRPS (a small recessed 
chin, abnormally arched palate) whereas Trps1∆GATA-Znf/∆GATA-Znf mice 
additionally showed a complete absence of vibrissae, the specialized sensory 
hairs found normally along the upper jaw. Unexpectedly, Trps1∆GATA-Znf/∆GATA-Znf 
mice died of neonatal respiratory failure due to abnormalities of the thoracic 
spine and ribs. Trps1+/∆GATA-Znf mice also developed thoracic kyphoscoliosis 
with age and had structural deficits in cortical and trabecular bones. The 
findings directly implicated the importance of the GATA-type Znf of TRPS1 in 
regulation of bone and hair development and suggested that skeletal 
abnormalities highlighted in descriptions of TRPS are only the extreme 
manifestations of a generalized bone dysplasia. 
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1.7  Aims 
 
This PhD work aimed at understanding the pathogenesis of the TRPS and 
identifying the potential target genes of the TRPS1 transcription factor by 
means of several projects. 
(I)  Identification of novel mutations in patients with TRPS type I followed 
by functional analysis of the missense mutations. 
(II)  Combination of RNA interference-mediated Trps1 silencing and cDNA 
microarray analysis to identify potential downstream genes of Trps1 in 
embryonic mouse fibroblasts. 
(III)  Generation of a TRPS1 transgenic mouse model. 
(IV) cDNA microarray analysis of different mouse embryonic tissues derived 
from wild type, Trps1+/∆GATA-Znf and Trps1∆GATA-Znf/∆GATA-Znf mice for 
identification of potential downstream genes of Trps1. 
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2.  MATERIALS AND METHODS 
 
2.1   Materials 
 
 
2.1.1      Chemicals 
 
The chemicals, if not otherwise indicated, were provided from Merck 
(Darmstadt), Sigma (Heidelberg) and GibcoBRL (Eggenstein). 
 
 
2.1.2  Standard solutions and mediums 
 
Standard solutions. 
 
10X loading buffer:       15% Ficoll, 0.25% Bromphenolblue  
   10 mM EDTA 
TAE buffer:    1 mM EDTA, 40 mM Tris-Acetate 
TE:       1 mM EDTA, 10 mM Tris-HCl 
 
Standard mediums (for bacterial culture) 
 
LB medium:  1% NaCl, 1% Trypton, 0.5% Yeast extract (Difco) 
LB plates:   LB medium, 1.2% Bacto-Agar (Biosciences 
     Clontech) 
LB X-Gal plates:  LB medium, 1.2% Bacto-Agar, 16 µg/µl X-Gal 
 
 
2.1.3  DNA and proteins markers 
 
DNA-markers:  1 kb DNA ladder, Invitrogen 
     pUC19 MspI digested, MBI Fermentas 
λ-DNA HindIII digested, Roche 
 
  
 13
Materials and methods 
Protein-marker:  prestained protein marker, Broad range, New 
England Biolabs 
 
 
2.1.4         Restriction enzymes 
 
The restriction enzymes used for this work were provided by Roche. 
 
 
2.1.5   Bacterial plasmids 
 
pBSGC79 pBluescript II Ks vector that carries the entire human 
TRPS1 cDNA (received from G. Chang)  
 
pNASSßCol2a1 pNASSß vector that contains promoter and enhancer of 
the mouse Col2a1 gene (received from Toshihisa Komori) 
 
pColTRPS1 pNASSß vector that carries the entire human TRPS1 cDNA 
under the control of the mouse Col2a1 promoter and 
enhancer (used to generate TRPS1 transgenic mice) 
 
HPG2-SV40 pGL3-control vector (Invitrogen) that carries a ∼1.7 kb 
promoter region of HPG2 (used as reporter plasmid in the 
luciferase reporter assay) 
 
LAPTM4B-pGL3b pGL3-basic vector (Invitrogen) that carries a ∼1.5 kb 
promoter region of LAPTM4B (used as reporter plasmid in 
the luciferase reporter assay) 
 
 
2.1.6  Trps1 knockout mice  
 
The Trps1 knockout mice (Malik et al., 2001) were generously provided by 
Dr. Ramesh A. Shivdasani from the Department of Medical Oncology, Dana-
Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 
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Genotype of the mice was assessed by RT-PCR (2.2.3), using primers chosen 
flanking the deleted mouse exon 5 (Appendix). 
 
 
2.2  Methods 
 
2.2.1  Nucleic acid purification 
 
2.2.1.1 DNA isolation from cells 
 
 
To isolate DNA from animal cells, for example from mouse fibroblasts, the 
cells were first detached from the dishes by using trypsin. The cell solution 
was then incubated O/N with 100 ng proteinase K (Roche), in 500 µl 75 mM 
NaCl/24mM EDTA and 10% SDS at 37 °C. After phenol/chloroform extraction 
the DNA was precipitated with 1 ml 100% ethanol and 50 µl NaOAc 3M. The 
DNA was fished with a glass pipette and washed with 70% ethanol and 
solved in TE. 
 
2.2.1.2 RNA isolation from animal cells and tissues 
 
RNA was extracted from the NIH3T3 cells and from mouse embryonic limbs 
and snouts according to the RNeasy Mini Handbook (QIAGEN). Frozen tissue 
samples or cell pellets were disrupted in buffer containing guanidine 
isothiocyanate (buffer RLT) and homogenized. For homogenization of cell 
lysates, QIAshredder spin columns were used. To disrupt and simultaneously 
homogenize animal tissues, the samples were applied within the Lysing 
Matrix D (Qbiogene) were agitated in the rotor-stator homogenizer FastPrep 
FP120 (Qbiogene, Carlsbad, CA) at 6.5 m/s for 45 sec with and then twice 
centrifuged (5 min/13000 rpm), before adding 70% ethanol and following the 
standard protocol. To obtain a better RNA quality for hybridization of the 
Affymetrix microarrays, after the QIAGEN protocol, the RNA was precipitated 
with 2.5 volumes 100% ethanol, 0.1 volumes NaOAc 3M and 1 µl Glycogen 
5mg/ml. After centrifugation 20 min at 13000 rpm at 4 °C the RNA pellet 
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was washed 2x with 75% ethanol and then dissolved in H2O to obtain a 1.5 
µg/µl concentration. 
 
 
2.2.1.2.1 DNase treatment of the RNA 
 
To avoid DNA contamination in the RNA samples two different DNase 
treatments were used. One option was offered by the RNase-Free DNase 
Set (QIAGEN) to use during the preparation. Shortly, according to the 
RNeasy Mini Handbook after the centrifugation with 70% ethanol, 350 µl 
buffer RW1 were pipetted into the RNeasy mini column and centrifuged (15 
sec, 10.000 rpm) to wash. 10 µl DNase I frozen solution (3U/µl) were 
added to 70 µl reaction buffer, gently mixed and the mix directly placed 
onto the RNeasy silica-gel membrane to incubate at least 15 min RT.  
The other treatment was performed by using 3 Units DNase I (Roche) 5 
mM MgCL2, 0.1 mM EDTA, 25 mM Tris-HCL, und 1 Unit RNase Inhibitor for 
5 µg RNA. 
 
 
2.2.2  Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction have been used to amplify specific DNA 
fragments by using the Perkin Elmer “PCR 9700 System” machines. Each PCR 
reaction was prepared in 50 µl of total volume combining the DNA template 
(1-10 ng of plasmid DNA or ∼150 ng of genomic DNA), 2.5 Units AmpliTaq-
Polymerase, 0.8-1.6 µM primers mix (forward and reverse), 800 nM dNTP-
Mix and reaction buffer (50 mM KCl, 10 mM Tris-HCl pH 8,3, 1,5 mM MgCl2, 
0,001 % Gelatine). After 5 min at 94 °C the following thermal cycling 
parameters were used for the amplification: 
15 s  DNA denaturation   94 °C 
15 s    primer annealing   50-68 °C 
30 s  primer extension  72 °C 
with a variable number of cycles between 25 and 35. 
To amplify PCR products longer than 1.5 kb the Platinum Taq DNA 
polymerase High Fidelity Kit (Invitrogen) was used following the 
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manufacturer protocol. To obtain genomic GC-rich PCR products region the 
BD AdvantageTM-GC 2 PCR Kit (BD Biosciences) was used following the 
manufacturer’s protocol. 
 
2.2.3  Reverse-Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
 
The RNA extracted from mammalian cells and/or tissues of different origins 
was reverse-transcribed in cDNA by using the GeneAmp RNA PCR Kit (ABI). 
The cDNA was then amplified by means of specific primer pairs. The 20 µl 
end volume of the reverse-transcription reaction contained: 100-500 ng RNA, 
5 mM MgCl2, 1 mM each dNTP, 2.5 Units MuLV (Murine Leukemia Virus) 
Reverse Transcriptase, 1 U RNase Inhibitor, 2.5 µM random hexamers and 2 
µl 10X PCR buffer. 
The following thermal cycle parameters were required for the reverse 
transcription: 
10 min  room temperature 
15 min  42 °C 
5  min   99 °C 
5  min     5 °C 
 
2.2.4  In vitro site-directed mutagenesis 
 
To introduce specific point mutations into an insert of interest ligated to a 
double-stranded DNA vector, the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) was used. Two primers between 25 and 45 bases in length 
containing the desired mutation were designed for the required PCR 
protocol. After the Dpn I digestion of the methylated, non-mutated parental 
DNA template, the PCR product was transformed into competent bacteria. 
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2.2.5  Restriction analysis 
 
Plasmid DNA was digested for analytic and preparative purposes using 10-
20 units restriction enzyme for each microgram DNA at 37 °C (or at the 
temperature indicated by the manufacturer, if different) for 2-20 h, in the 
suitable digestion buffer. For O/N digestion 1X BSA was included in the 
reaction 
 
 
2.2.6  Agarose gel electrophoresis 
 
DNA fragments were separated in relation to their size by means of 1-2 % 
agarose gel electrophoresis. The powdered agarose was melt in 1 X TAE 
buffer, cooled to about 60 °C and supplemented with a final concentration 
of 0.5 µg/ml Ethidium bromide (EtBr). The DNA samples were mixed with 
the gel-loading buffer and a voltage of 1-5 V/cm (measured as the distance 
between the electrodes) was applied to let the DNA migrate. The presence 
of EtBr allows the gel to be examined by ultraviolet illumination at any 
stage during electrophoresis. 
 
 
2.2.7  Purification of DNA fragments 
 
2.2.7.1 Purification of PCR products 
 
The PCR products were purified by using the Microcon columns (Amicon). 
First the PCR reaction was filled up to 500 µl with H20 and applied to the 
column. After centrifugation (15 min, 2300 rpm) the column was once again 
filled up to 500 µl with H20, centrifuged again (15 min, 2300 rpm) and 15-30 
µl H20 were then pipetted into the column. The column was finally placed 
inverted in a new reaction tube and centrifuged (4 min, 2300 rpm). 
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2.2.7.2 Purification of restriction products 
 
To purify double-stranded DNA fragments ranging from 70 bp to 4 kb from 
enzymatic reactions the MinElute Reaction Cleanup Kit (QIAGEN) was used 
following the manufacturer’s protocol. 
 
 
2.2.7.3 Gel slice extraction 
 
To extract DNA fragments from agarose gels, the QIAquick gel extraction 
kit (QIAGEN) was used. According to the protocol, the gel slice containing 
the DNA fragment of interest was excised from the agarose gel with a 
scalpel, transferred in one reaction tube with 3 volumes buffer QG and 
incubated 10 min at 50 °C. The solution was then applied to the QIAquick 
column. After centrifugation (1 min, 10000 rpm) the sample was washed 
with PE buffer and finally eluted in 30-50 µl H20. 
 
 
2.2.8  Ligation 
 
The ligation reaction was set up in 10 µl total volume containing 10-20 ng of 
vector DNA and insert DNA in a molar ratio 3:1 insert DNA: vector DNA. The 
reaction was incubated 2-3 h RT in the presence of 1 µl (5 units) of T4-DNA-
Ligase (Roche) and 1 µl of 10X ligation buffer (Roche). To clone PCR 
products, the pGEM-T easy vector system I Kit (PROMEGA) and the pCR 2.1-
TOPO cloning kit (Invitrogen) were used following the manufacturer’s 
protocol.  
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2.2.9  Bacterial transformation 
 
 
2.2.9.1 Bacteria strain 
 
E.coli DH5α   F', endA1, hdR17, (rk-mk+), supE44, thi-1,
 recA1, gyrA, (Nalr), relA1, D(lacIZYA-argF), 
U169, deoR,  
 
(Φ80dlacD(lacZ)M15) 
 
 
2.2.9.2 Transformation of competent bacteria (heat-shock 
method) 
 
The preparation of competent bacteria (bacterial cells that can take up DNA) 
was made by Stefanie Groß. 
5 µl of the ligation reaction or 1-10 ng plasmids DNA were added to 50 µl of 
competent cells and the mix was stored on ice for 30 min. The tube was then 
transferred in a water bath at 42 °C for 2 min. After rapid transfer on ice, 
450 µl of LB medium were added and the mix was then transferred to a 
shaking incubator set at 37 °C for 1 h. Next, the transformed cells were 
gently spread over the surface of the agar plate and at 37 °C O/N incubated. 
 
 
2.2.10         Plasmid DNA isolation 
 
 
2.2.10.1      Small-scale analytic preparation of plasmid DNA 
 
A single bacterial colony was cultured at 37 °C O/N in LB medium (plus 100 
µg/µl ampicillin as final concentration). After centrifugation of the culture (4 
min/5000 rpm), the bacterial pellet was resuspended in 300 µl of P1 buffer 
and lysed by adding 300 µl of P2 buffer. 300 µl P3 buffer was then added to 
precipitate the SDS-protein complex. The mix was centrifuged (15 
min/10.000 rpm) and the supernatant transferred in a new reaction tube in 
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the presence of 100 % ethanol to precipitate the DNA. After centrifugation 
(25 min/13.000 rpm) the DNA pellet was washed once with 70% ethanol, 
dried and dissolved in 20-50 µl H20. 
 
buffer P1:  10 mM EDTA 
  50 mM Tris-HCl, pH 8,0 
  100 µg/ml RNaseA 
 
buffer P2                    0,2 M  NaOH   
1 %     SDS 
 
buffer P3:  3 M     potassium acetate 
     acetic acid up to pH 
 
 
2.2.10.2      Large-scale preparation of plasmid DNA 
 
To prepare a large amount of plasmid DNA, 250 ml O/N bacterial culture was 
centrifuged and DNA was purified from bacterial pellet in accordance with a 
modified alkaline lysis procedure, followed by binding of plasmid DNA to 
QIAGEN Anion-Exchange Resin under appropriate low-salt and pH conditions 
(QIAGEN-System).   
 
 
2.2.11 Quantification of nucleic acids concentration 
 
The exact concentration of DNA and RNA was determined by measuring the 
absorbance at wavelength of 260 nm in the Ultrospec III (Pharmacia). An 
absorbance of 1 unit at 260 nm corresponds to 50 µg of DNA and 40 µg of 
RNA per ml in water. 
The ratio of the readings at 260 nm and 280 nm (A260/A280) provides an 
estimate of the purity of the nucleic acid solution with respect to proteins, for 
example. Pure DNA and pure RNA have an A260/A280 ratio of 1.8-1.9 and 1.9-
2.0, respectively. 
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2.2.12 Sequencing 
 
The sequencing reactions were performed by using the PrismTM BigdyeTM 
TerminatorCycle ReadyReactionKit (ABI). For a single reaction in 10 µl total 
volume were used 4 µl of the fluorescent labelled terminators (Bigdye) 
supplied in the Kit , 300-500 ng plasmid DNA or 200-400 ng PCR products 
and 5 pmol of the respective primer. The following thermal cycling 
parameters were used for 25 cycles: 
10 sec     96 °C 
 5 sec     45-60 °C 
 4 min     60 °C 
The sequencing products were then precipitated with 100% ethanol, washed 
with 70% ethanol, and resuspended in 20 µl HiDi FORMAMIDE (ABI). The 
sequencing of plasmid inserts and PCR products has been carried out by 
means of the 3100 Genetic Analyzer (ABI PRISM), which is an automatized 
capillary electrophoresis system that can separate, detect and analyze up to 
16 capillaries of fluorescently labelled DNA fragments in one run.  
 
 
2.2.13 Microarray analysis 
 
Total RNA was extracted from NIH3T3 cells transfected with specific 
oligonucleotides (see 2.2.19) and from mouse tissues (whole limbs and 
snouts) removed from Trps1 knockout embryos (see 2.1.6) to hybridize 
Affymetrix U74Av2 and MOE430A oligonucleotides arrays, respectively. 
Hybridization, washing and scanning were performed by Dr. Ludger Klein-
Hitpass (Institut für Zellbiologie, Uniklinikum Essen) following standard 
Affymetrix protocols (Technical Manual).  
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2.2.14  Real-time PCR 
 
To obtain relative expression data of several genes in wild type and mutant 
mice real-time quantitative PCR was used. Real-time PCR was performed in 
triplicate, starting from 100-200 ng RNA (always the same amount of RNA is 
required for the same set of experiments) for the 20 µl finale volume 
reverse-transcriptase reaction (2.2.3) on ABI Prism 7000 (ABI) using 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as endogenous control 
(all the assays, called Assay-On-Demand AOD, were supplied by ABI). 
Calculation was performed using values of delta ∆ cycle threshold (∆Ct) using 
wild type mice as calibrator. For each experimental sample, the Ct of the 
target, normalized to the endogenous control and relative to the calibrator, is 
given by: 2-∆∆Ct (Livak and Schmittgen, 2001). 
Following the manufacturer protocol, each reaction in a 96-well Optical 
reaction Plate (ABI PRISM) was set up as follows: 1 µl from the RT reaction, 
1 µl AOD, 10 µl TaqMan Universal PCR master Mix and H20 up to 20 µl. The 
following thermal cycling parameters were used: 
one cycle 50 oC   2 min 
one cycle 95 oC   10 min 
40 cycles 95 oC   15 sec 
            60 oC   1 min 
 
 
2.2.15 Mutation analysis of the TRPS1 gene 
 
DNA of patients and control individuals was prepared from peripheral blood 
lymphocytes from Stefanie Groß. Genomic PCRs were performed in reactions 
(50 µl total volume) containing 150 ng genomic DNA under standard 
conditions (2.2.2). Both strands were sequenced (2.2.12) using the same 
primers as for the amplification and analysed by means of the program 
Sequencher. The primer sequences were published by Momeni et al. (2000). 
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2.2.16 Cell culture 
 
 
2.2.16.1 Cell lines 
 
NIH3T3 mouse embryonic fibroblasts, adherent (ATCC CRL 1658) 
COS-7 monkey kidney fibroblasts, SV40 transformed, adherent 
 (ATCC CRL 1651) 
HeLa human cervix adenocarcinoma epithelial cells, adherent  
 (ATCC CCL-2) 
 
 
2.2.16.2 Cell cultures medium 
 
DMEM (Gibco) Dulbecco’s Modified Eagle’s Medium 
with 4500 mg/l Glucose + L-Glutamine 
+ Pyruvate  
Fetal calf serum, FCS (PAA)  10% final concentration 
Antibioticum/Antimicoticum   1% final concentration 
100 x (PAA)         
Gentamycin     1% final concentration 
 
 
2.2.16.3 Growth and maintenance of live cell cultures 
 
The cells were grown in DMEM supplemented with FCS, 
Antibioticum/Antimicoticum and gentamycin at 37 0C under a 5% CO2 
atmosphere. Cells were disaggregated and detached routinely with 2-3 ml 
Trypsin EDTA 1x (Gibco) and replated at a split ratio of 1:10-1:5.  
 
 
 
 
  
  
 24
Materials and methods 
  
2.2.17 Luciferase reporter gene assay  
 
To assess the capability of TRPS1 to influence the expression of some of its 
potential downstream genes, reporter gene experiments were performed. 
Transient transfection assays were carried out using FuGENE 6 (Roche). The 
day before the transfection the cells (HeLa and COS-7 cells) were trypsinized 
and transferred in a 6-well plate to have about  2X105 cells/well in two ml 
DMEM medium supplemented with 10% FCS but without antibioticum and 
antimicoticum. FuGENE was used in a ratio 2:1 volume FuGENE (µl): mass 
DNA (µg). 0.5 µg of the reporter plasmid, 1 µg of the TRPS1 expression 
plasmid and 1 µg of the XGATA4 expression plasmid were used. The 
individual DNA mixtures were adjusted with respective amounts of empty 
plasmids. After 48 h the transfected cells were lysed with 100 µl of 1x lysis 
buffer provided from the Luciferase Reporter Gene Assay High Sensitivity Kit 
(Roche), scraped off the plate using a rubber policeman. The solubilized cells 
were transferred in reaction tubes and to remove cellular debris the lysates 
were spinned for few sec at 13000 rpm. Twenty µl of the cell extracts were 
transferred into an appropriate luminometer counter device and the reactions 
were started by injecting 100 µl of the luciferase assay reagent (Roche). The 
measurement of light emission by luminometry (LUMAT LB9507) was started 
within 0.5 –10 s after adding luciferase assay reagent for a period of 1– 5 s. 
   
 
2.2.18  Proteins 
 
2.2.18.1 Total cell protein extract 
 
To extract their total protein content, the cells were detached from the Petri 
dish by using trypsin and then washed with PBS. After centrifugation (5 min, 
1000 rpm) the pellet was resuspended in Flag-Lysis Buffer. 
Flag-Lysis-Puffer:      25 mM  Tris-HCl, pH 7,4 
 150 mM  NaCl 
 1 mM   CaCl2 
 1 %   Triton-X-100 
 1:1000  DTT (1M) 
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Proteinase-           100 mg/ml Phenylmethylsulfonyl Fluoride 
Inhibitors:  (PMSF) 
                1 mg/ml   Pepstatin 
 1 mg/ml   Bestain 
 in 80 % Methanol und 20 % DMSO 
 
 1 mg/ml Aprotenin 
 1 mg/ml E64 
 1 M  NA3VO4 
 1 M  Na2MnO4 
 in bidest H20 
 
 
 
2.2.18.2     Quantification of proteins in solution  
 
 
The Bradford assay (Bradford, 1976) works by the action of Coomassie 
brilliant blue G-250 dye (CBBG) contained in the Bradford reagent, which 
binds specific amino acid residues exposed on the surface of the protein 
undergoing quantification. Two µl of the protein solution were added to 798 
µl H20 and to 200 µl Bradford reagent and 5 min RT incubated. It is 
monitored at 595 nm in a spectrophotometer by measuring the CBBG 
complex with the protein. 
 
Bradford reagent: 100 mg CBBG 
 50 ml  ethanol 
 100 ml phosphoric acid 
 up to 200 ml H20 
 
 
2.2.18.3 Discontinous SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
To separate protein samples by size, a discontinuous SDS gel electrophoresis 
(SDS-PAGE) was used. Two different polyacrylamide gels, a collecting and a 
separating gel (7.5-10 % in relation to the size of the protein to analyse) 
were prepared. The collecting gel was layered on the top of the separating 
gel in a gel cassette supplied by the Mini-PROTEAN 3 Cell Kit (BIO RAD). The 
gel cassette was then placed into the inner chamber containing the electrode 
assembly. 10-20 µg from cell protein extract were denaturated at 95 °C for 
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10 min in a 4 X SDS-Probe buffer, loaded onto the gel and let migrate in 1 X 
Running buffer at 20-30 mA for 2-3 h. 
 
Separating gel buffer:  1.5 M  Tris-HCl, pH 8,8 
   0.4 %  SDS 
 
Collecting gel buffer:   0.5 M  Tris-HCl, pH 6,8 
   0.4 %  SDS 
 
10x SDS-running buffer:   1.25 M Tris-Base 
   2 M  Glycin 
   1 %  SDS 
 
4x SDS-Probe buffer:  62 mM  Tris-HCl, pH 6,8 
   2 %  SDS 
   10 %  Glycerin 
   5 %  DTT 
   5 %  ß-Mercaptoethanol 
   0,025 % Bromphenolblue 
 
 
  
2.2.18.4 Western-blot and protein detection 
 
To transfer proteins from the SDS polyacrylamide gel to a nitrocellulose 
membrane the TRANS-BLOT semi dry transfer cell kit (BIORAD) was used. 
The transfer cassette was assembled as follows from the bottom to the top: 
five layers of Whatman 3MM paper, the Hybond C Membrane (Amersham), 
the polyacrylamide gel and on the top five layers of Whatman 3MM paper. 
Each component was previously soaked with transfer buffer. The negative 
charge was on the side of the gel and the positive charge on the side of the 
membrane. The transfer was accomplished in 1.5 till 2 h at 1.5 mA/cm2. All 
sites on the membrane which did not contain blotted protein from the gel 
were "blocked" with blocking solution to prevent unspecific binding of the 
antibody to the membrane. To detect one specific protein the nitrocellulose 
membrane was incubated with a primary antibody (a rabbit polyclonal anti-
TRPS1 antibody SN653 [Chang et al., 2002] for the detection of the human 
TRPS1 and the mouse Trps1) at 4 °C O/N, usually diluted 1:1000 in blocking 
solution. The membrane was washed with PBS for 1 h. In order to detect the 
antibodies which have bound, a second antibody conjugated with Horseradish 
peroxidase (HRP) was added (1:5000 in blocking solution). Excess of second 
antibody was washed free of the blot with PBS. 800-1000 µl of the 
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SuperSignal West Dura Kit (Pierce) were applied on the membrane 
immediately before placing the Film Super RX (Fuji Medical X-Ray Film). After 
2-3 minutes the film was developed with the developer G153A and G153B 
(AGFA) and the fixer G354 (AGFA). 
 
Transfer-Puffer: 5,82 g/l Tris-Base 
 2,93 g/l Glycin 
 3,75 ml 10 % SDS 
 200 ml Methanol 
 ad 1000 ml bidest H20, 
 
Blocking solution: 2 % powdered milk 
 in PBS 
  
 
 
2.2.19 RNA interference  
 
To achieve the post-transcriptional silencing of Trps1 gene in mouse 
fibroblasts, 21-nucleotide small interfering RNAs (siRNA) were transfected in 
NIH3T3 by using the OligofectamineTM Reagent (Invitrogen). 
24 h before transfection the cells were trypsinized and transferred into a   
12-well plate to have about  1X105 cells/well in two ml DMEM medium 
supplemented with 10% FCS but without antibioticum and antimicoticum. 
Three µl of Oligofectamine were diluted in 12 µl DMEM and incubated 5 to 10 
min RT. Ten µl of the siRNA (100nM final concentration) were diluted into 50 
µl DMEM medium (without anything) and then added to the diluted 
Oligofectamine. The mix was carefully mixed and incubated at RT for 15-20 
min. The mixture was then dropwise added to the cells. The day after the 
transfection the medium was changed with full medium and the cells 
harvested 48 h after transfection. The total protein cell extract was then 
prepared and afterward the proteins were separated in a SDS-PAGE. The 
Western-blot was first incubated with the specific primary antibody, then with 
the second antibody and after exposure the film was developed. Immunoblot 
with antibody against lamin A was used as loading control.  
 
Trps1 sequences homologous to the oligonucleotides: 
 
Mouse Trps A  AACAGCTACAGAGAGCAAGGT 
Mouse Trps B  AAAGGCCACTGAGGAAACAGG 
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Mouse Trps C  AACATTATGGCAAGCAGCACG 
(provided by Dr. Matthias Truss, Charité University, Berlin) 
 
 
2.2.20  TRPS1 transgenic mice 
 
The transgene includes the entire coding region of the human TRPS1 gene 
carrying a missense mutation at position 2701 (introduced by using the 
Mutagenesis Kit) (see Appendix for primer sequences). The mutated human 
TRPS1 cDNA was cut out of the pBSGC79 vector by using EcoRI and BamHI 
sites. The pNASSßCol2a1 was digested with NotI and the linear plasmid was 
ligated with specific linkers containing a EcoRI and a BglII sites (see 
Appendix), which were used to clone the human TRPS1 cDNA into the 
pNASSßCol2a1. The purified transgene, which was linearized with AatII and 
BspLU11I and was about 7.3 kb in length, was microinjected into the male 
pronucleus of fertilized single-cell eggs. These eggs were then surgically 
implanted into the oviduct of pseudo pregnant recipient female mice. The 
work required for the generation and preservation of the mice colonies was 
performed by Wojciech Wegrzyn and Ralph Waldschütz (Institut für 
Zellbiologie, Uniklinikum Essen), respectively. The southern blot analysis for 
the identification of transgenic animals was made by Christian Kosan (Institut 
für Zellbiologie, Uniklinikum Essen). 
 
 
2.2.20.1  In situ hybridisation 
 
In collaboration with the group of Andrea Vortkamp (Institut für 
Molekulargenetik, Max-Planck-Institut, Berlin) in situ hybridisation studies 
were performed in TRPS1 transgenic embryos to look for abnormal 
expression patterns of genes involved in bone development. Mouse limb 
explants from E14.5, E16.5 and E18.5 embryos were fixed in 4% 
paraformaldehyde at 4 oC and embedded in paraffin. The paraffin tissue 
sections were deparaffinized in xylenes and dehydrated through a graded 
series of EtOH (100%, 95%, 85%, 70%, 50% and 30 %). The sections were 
then digested with proteinase K (20 µg/ml) in PBS for 5 min and acetylated 
(0.1M Triethanolamine, 0.25% acetic anhydride) for 10 min.  
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For labelling the antisense riboprobes, a transcription reaction was set up 
with 1 µl (about 300 ng) of linearized DNA vector containing the desired 
insert and a T3 or T7 promoter, 2 µl of 10x transcription buffer, 2 µl of 5mM 
dNTPs mix, 1 µl of 40 U/µl RNAsin (inhibitor of RNAse), 2 µl of 20 U/µl T3 or 
T7 polymerase (according to the vector), 4 µl UTP33 (80 µCi) and 8 µl H20. 
After incubation for 1 h 30 min at 37 0C, 20 U DNAse (Roche) were added for 
20 min at 37 0C and then the RNA was precipitated with EtOH 100%. The 
pellet was washed with 80% EtOH and dissolved in 50 µl H20. 1 ml of the 
melt hybridisation buffer was added to the 50 µl antisense riboprobe and 
carefully mixed. The probes can be stored maximum one week at -20 0C. 
Before use they were heated up for 5 min at 95 0C. 
Tissue sections were hybridized O/N (50 µl hybridization buffer on every 
slide) in 50% formamide and 5% SSC. Following hybridisation, the sections 
were washed in 2x SSC and digested with 20 µg/ml RNase A in 1xSSC. After 
the RNase digestion, the slides were washed at 55 oC in 2x SSC with 50% 
formamide and in 2x SSC. The sections were dehydrated through a graded 
series of EtOH, air-dried and autoradiographed in NTB-2 (Kodak) emulsion. 
Section were developed in D-19 developer (Kodak) for 5 min at 15 oC, 
stopped in water for 15 sec and fixed to Kodak fixer for 15 min. After 
washing, the slides were counterstained with toluidine blue (Sigma).  
Probes for in situ hybridisation were as follows: rat ColII (type II collagen), 
mouse ColX (type X collagen), mouse Ihh (Indian hedgehog), mouse PTHrP 
(parathyroid hormone-like peptide), mouse Ptch (Patched), mouse Mmp13 
(Matrix metalloproteinase 13) and mouse Trps1.  
 
 
2.2.20.2  Safranin staining 
 
In collaboration with the group of Andrea Vortkamp (Institut für 
Molekulargenetik, Max-Planck-Institut, Berlin) this method was used for the 
detection of cartilage in paraffin-embedded tissue sections. The sections were 
deparaffinized, hydrated to distilled water and then stained with Weigert’s 
iron hematoxylin working solution for 2-3 min. Afterward the sections were 
washed in running tap water, stained with  fast green solution for 2 min, 
rinsed quickly with 1% acetic acid and finally stained in 0.1% Safranin O 
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(Aldrich Chemical Co) for 5 min. Next the sections were dehydrated and 
cleared with 95% EtOH, 100% EtOH and xylene, using two changes each, 2 
min each. 
 
 
2.2.20.3  Mouse skeletal preparation 
 
For staining and visualisation of whole-mount cartilage and ossified skeletal 
elements, E16.5 embryos and adult mice were dissected and stained with 
alizarin red (Sigma-Aldrich) and/or alcian blue 8GX (Sigma-Aldrich). Skin and 
internal organs were first removed from the specimens, if adults. For 
embryos this step was not necessary. The samples were fixed 2-3 days in 
95% EtOH  RT and then placed in acetone to remove fat for 2 days followed 
by staining with 0.03% alcian blue in 4:1 95% EtOH:glacial acetic acid at 37 
°C (4 days for the embryos and 5-7 days for the adults). The samples were 
washed in 95% ethanol for 1 day RT (the ethanol was periodically changed) 
and then immersed in 2% KOH (about 1 h for the embryos, 12-48 h for the 
adults). As soon as the skeleton was clearly visible trough the surrounding 
tissue the samples were stained in 0.01% alizarin red in 1% KOH O/N at RT.  
The samples were then processed through a graded series of glycerin 
(Merck) in KOH solutions: 
 20%    1 volume glycerin / 4 volumes 1% KOH      
 50%    1 volume glycerin / 1 volume 1% KOH        
 80%    4 volumes glycerin / 1 volume 1% KOH      
and stored in 100% glycerol. 
The blue tissues represented the cartilage and the red tissues represented 
the bone. 
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3  RESULTS 
 
3.1  Mutation analyses 
 
Mutation analyses on the TRPS1 gene were performed in the attempt to 
augment the spectrum of TRPS1 mutations and to identify functional 
domains of the TRPS1 transcription factor. 
Ten novel mutations were identified: seven nonsense mutations (patients 
cases 17689, 16851, 17601, 17688, 16698, 17680 and 16687), two 
missense mutations (patients cases 18712 and 16908) and one splice site 
mutation (patient case 18058) (Table 1). To exclude a further mutation, the 
entire coding region as well as the noncoding exon 2 was sequenced in all 
cases, but no additional mutation was found (for the primer sequences: 
Momeni et al., 2000). 
 
Table 1 Ten novel TRPS1 mutations in patients with TRPS type I. 
 
Case Familial 
 
Mutationa 
 
Location Amino acid changeb 
17689 yes -36-+72del exon 3 
 
deletes translation start 
codon 
16851 no 1650T>A exon 4 Y550X 
17601 yes 2718-2719delCT exon 6 novel stop codon 936 
17688 yes 2722C>T exon 6 R908X 
16698 yes 2745T>A exon 6 Y915X 
17680 no 2770C>T exon 6 Q924X 
18058 yes IVS6+2G>T IVS6 in frame skipping of exon 6 
18712 yes 2854C>T exon 7 R952C 
16687 yes 3436-3472del exon 7 novel stop codon 1152 
16908 yes 3649T>C exon 7 C1217R 
a Nucleotide numbers refer to the TRPS1 cDNA sequence  b Amino acid numbers refer to the deduced peptide sequence 
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The 2854C>T transition leads to the exchange of arginine to cysteine at 
position 952 situated in the predicted NLS (946-952 aa) in the TRPS1 
protein. This was one of the first two missense mutations in the TRPS1 
gene that did not affect the GATA zinc-finger domain and that lead to TRPS 
type I.  A functional study (Kaiser et al., 2004) using, among other, this 
missense mutation, showed that the predicted NLS was indispensable for 
translocation of TRPS1 into the nucleus and that a single amino acid 
exchange was sufficient to prevent nuclear localization. 
The 3649T>C transition leads to the exchange of cysteine to arginine at 
position 1217 situated in the first C-terminus Ikaros-like zinc finger. 
Ongoing functional studies investigate whether this mutation in the TRPS1 
protein might interfere with the repressional function of the TRPS1 
transcription factor (Kaiser, pers. communication). 
 
 
3.2  RNA interference and microarray analysis 
 
RNA interference (RNAi) is the process of sequence-specific, post-
transcriptional gene silencing in animals and plants, initiated by double-
stranded RNA that is homologous in sequence to the silenced gene 
(McManus and Sharp, 2002; Hammond et al., 2001). The mediators of 
sequence-specific messenger RNA degradation are 21- and 22-nucleotide 
small interfering RNAs (siRNAs) (Elbashir et al., 2001). 
RNA interference experiments were performed to silence Trps1 in NIH3T3 
cells. To identify potential downstream genes of Trps1, the expression 
profile of cells where Trps1 was silenced was compared with that of control 
cells. This procedure made possible the detection of either genes 
upregulated in the treated cells, whose expression is normally repressed by 
Trps1 or genes downregulated in the treated cells, whose expression is 
normally activated by Trps1. 
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3.2.1  Trps1 silencing in NIH3T3 cells 
 
By using short double-stranded RNAs (or small interfering RNAs, siRNAs), 
homologous in sequence to the Trps1 gene, the expression of the Trps1 
genes was silenced in NIH3T3 cells. Three siRNAs were available: Mouse 
Trps A, Mouse Trps B, and Mouse Trps C (see Materials and methods 
2.2.19). They were chosen following important criteria: (1) they were 
composed of 21-nucleotides sense and 21-nucleotides antisense strands, 
paired in a manner to have a 2-nucleotides 3’ overhang, which contributes 
to the specificity of target recognition; (2) they were selected from the 
Trps1 cDNA sequence beginning about 60 nucleotides downstream of the 
start codon; (3) they contain about 50% G/C nucleotides; (4) they are 
Trps1 specific. The most significant decrease of the Trps1 protein 
expression in comparison with the control (NIH3T3 cells treated only with 
the transfection reagent Oligofectamine, without siRNA) was obtained 
transfecting the cells with the Mouse Trps A siRNA as proved by Western 
blot analysis (Fig. 5). As loading control, the lamin A expression was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5 Western-blot analysis of Trps1 after transfection of NIH3T3 cells with 100 nM 
of siRNA Mouse Trps A, Mouse Trps B and Mouse Trps C. A rabbit polyclonal anti-
TRPS1 antibody SN653 (Chang et al., 2002) was used for the protein detection. As 
loading control the lamin A expression was detected with a specific lamin A 
antibody (Santa Cruz Biotechnology).  
 
Trps1 
NIH3T3 
control 
Mouse 
TrpsA 
Mouse 
Trps B 
Mouse 
Trps C 
lamin A 
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3.2.2  cDNA microarray analysis 
 
Three independent transfections of NIH3T3 cells with siRNA Mouse Trps A 
were performed. In experiments 1 and 2 it was still possible to detect a 
slight expression of Trps1 after siRNA transfection, whereas in experiment 3 
Trps1 was totally silenced (Fig. 6). RNA was isolated from the three control 
NIH3T3 samples and from the three treated NIH3T3 samples to hybridize 
six Affymetrix U74Av2 arrays.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Western-blot analysis of Trps1 after three independent NIH3T3 transfections 
with 100 nM of siRNA Mouse Trps. As loading control the lamin A expression was 
detected with a lamin A antibody. 
 
 
The expression profiles of the three independent treated samples were 
compared with those of the controls. Genes were considered as 
differentially expressed when showing at least a 1.5-fold difference in the 
mean expression level between treated  and untreated samples with a 
standard deviation of less than 25% between individual samples from one 
group. Moreover, genes were considered differentially expressed when 
scored as “absent” in at least two of the three cell cultures of one group 
and the calls in the other group were scored as „present” in all three cell 
cultures. In this case, the fold change was defined as >1.5 for the 
upregulated genes and <-1.5 for the downregulated genes. Following these 
parameters 59 genes were found to be abnormally expressed in the treated 
experiment 1 
experiment 2 
experiment 3 
                                
  Mouse Trps A 
loading control 
control  
NIH3T3 
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cells, 30 downregulated (Table 2) and 29 upregulated (Table 3). The 
highest fold change in the mean expression values (2.1) was found for the 
Hoxa4 (homeo box A4), which was upregulated in the treated cells. Most of 
the differentially expressed genes encoded for proteins involved in 
transcription regulation, signal transduction and in intracellular transport 
(Fig. 7). For 50% of the genes found to be downregulated in the treated 
cells the putative function of their gene products was unknown. 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
Fig. 7 Functional classification of the abnormally expressed genes in the treated 
NIH3T3. Most of the genes encode proteins involved in transcription, transport and 
signal transduction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upregulated genes  
 
Downregulated genes  
3% 3%
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7%
17%
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Table 2 Classified list of the genes downregulated in the treated NIH3T3  
GenBank 
accession 
number 
Affymetrix 
ID 
Fold 
change 
Description 
Gene 
Symbol 
Acid nucleic metabolism 
AA863742 104456_at <-1.5 methyltransferase-like 3 Mettl3 
Transcription 
X60136 100032_at -1.5 trans-acting transcription factor 1 Sp1 
X56690 96775_at -2.0 chromobox homolog 1 (Drosophila HP1 beta) Cbx1 
AI847650 94945_at <-1.5 hypertension-related, calcium regulated gene Hcarg-
pending 
L12147 92535_at <-1.5 early B-cell factor 1 Ebf1 
 
Signal transduction 
AA919832 104742_at -1.5 microsomal glutathione S-transferase 2 Mgst2 
 
AF047704 102043_at <-1.5 tuftelin 1 Tuft1 
AF040094 94398_s_at <-1.5 inositol polyphosphate-5-phosphatase B Inpp5b 
AF051367 94171_at <-1.5 integrin beta 2-like Itgb2l 
 
Transport 
AA683883 99112_at <-1.5 solute carrier family 25 (mitochondrial carrier; 
dicarboxylate transporter), member 10 
Slc25a10 
AI844369 102320_at <-1.5 sorting nexin 12 Snx12 
M59446 94140_at <-1.5 macrophage scavenger receptor 1 Msr1 
Protein conformation synthesis and degradation 
U79523 100496_at <-1.5 peptidylglycine alpha-amidating monooxygenase Pam 
AI845578 99647_at <-1.5 ribulose-5-phosphate-3-epimerase Rpe 
AW120756 96848_at <-1.5 inositol polyphosphate-5-phosphatase E Inpp5e 
 
Unknown     
AW122812 103738_at <-1.5 hypothetical protein MGC47434 
 
 
AI605538 104442_at <-1.5 RIKEN cDNA A830021G03 gene 
 
 
AI152789 93411_at <-1.5 RIKEN cDNA 2900057C09 gene 
 
 
AW048989 99360_at <-1.5 serine active site containing 1 
 
 
C88243 102130_f_at <-1.5 Mus musculus transcribed sequence  
AW050290 103375_at <-1.5 RIKEN cDNA 2810406K24 gene 
 
 
AW124941 93776_at <-1.5 RIKEN cDNA 1500001L15 gene 
 
 
U79962 103101_at <-1.5 TAR (HIV) RNA binding protein 2 
 
Tarbp2 
AI852257 100904_at <-1.5 DNA segment, Chr 14, ERATO Doi 209, expressed 
 
 
AW045230 100987_f_at <-1.5 hsp70-interacting protein Hspbp1-
pending 
AW123795 104035_at <-1.5 RIKEN cDNA A930019L04 gene 
 
 
AI844196 93143_at <-1.5 RIKEN cDNA 1190005I06 gene 
 
 
AA675006 103767_f_at <-1.5 cDNA, clone:B930086G17  
 
 
 
AI642262 92245_at <-1.5 RIKEN clone:6720481A07  
 
 
AV361953 162168_r_at <-1.5 Mus musculus transcribed sequence  
 
 
 
AW122812 
 
103738_at 
 
<-1.5 
 
hypothetical protein MGC47434 
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Table 3 Classified list of the genes upregulated in the treated NIH3T3                                      
 
 
 
GenBank 
accession 
number 
Affymetrix 
ID 
Fold 
change 
Description 
Gene  
Symbol 
Acid nucleic metabolism 
X92410 92410_at 1.5 RAD23a homolog (S. cerevisiae) Rad23a 
Cell growth, division, defense and death  
AB005654 
 
99036_s_at 
 
>1.5 mitogen activated protein kinase kinase 7 
Map2k7 or 
Mkk7 
Metabolism 
AI846600 97511_at >1.5 monoglyceride lipase Mgll 
AV295044 161524_r_at >1.5 glucose phosphate isomerase 1 Gpi1 
Transcription     
AV279579 162402_r_at 2.1 homeo box A4 Hoxa4 
AB010152 103810_at 1.8 transformation related protein 63 
Trp63 or 
p63 
X73572 98367_at 1.5 homeo box D3 Hoxd3 
X83971 103546_at 1.5 fos-like antigen 2 
Fosl2 or 
Fra2 
J03750 101980_at >1.5 
RNA polymerase II transcriptional 
coactivator 
Rpo2tc1 
M58564 93944_r_at >1.5 zinc finger protein 36, C3H type-like 2 Zfp36l2 
Signal transduction 
AI852332 99497_at 1.6 ADP-ribosylation factor interacting protein 2 Arfip2 
X02891 92783_at 1.5 growth hormone Gh 
AF063229 103809_r_at 1.5 dynein, cytoplasmic, intermediate chain 1 Dncic1 
AF092050 98291_at 1.5 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 
B3gnt1 
U10094 97761_f_at >1.5 
killer cell lectin-like receptor, subfamily A, 
member 7 
Klra7 
Transport 
M21530 93895_s_at 1.8 inositol 1,4,5-triphosphate receptor 1 Itpr1 
L20343 100757_at 1.6 
calcium channel, voltage-dependent, beta 2 
subunit 
Cacnb2 
AI843327 96276_r_at 1.5 SM-11044 binding protein 
Smbp-
pending 
AV210775 161684_r_at >1.5 lipocalin 2 Lcn2 
AV362816 161784_f_at >1.5 steroidogenic acute regulatory protein Star 
Protein conformation synthesis and degradation 
AI840454 101513_at 1.6 prefoldin 5 Pfdn5 
AW049679 97331_at 1.5 calpain 10 Capn10 
AV374357 162205_f_at >1.5 RIKEN cDNA 2010001P08 gene  
Unknown     
AV356223 161471_f_at 1.7 hypothetical protein 5730409O11  
AW046757 102036_at 1.6 RIKEN cDNA 1810004B07 gene  
AV210958 161519_f_at 1.5 RIKEN cDNA 1700037H04 gene  
AA833293 104415_at 1.5 RIKEN cDNA 3110052D19 gene  
AA636966 103992_f_at >1.5 Nur77 downstream protein 1  
AV346841 161462_r_at >1.5 
 
RIKEN cDNA 6720476A01 gene 
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So far, no further analyses of the differentially expressed genes were 
performed, because of the opportunity to analyze different tissues from the 
Trps1 knockout mice (Malik et al., 2002), provided by Dr. Shivdasani (see 
2.1.6), which were considered better material for the identification of Trps1 
target genes.  
 
 
3.3  Generation and characterization of TRPS1 transgenic 
mice 
 
3.3.1  Generation of transgenic mice 
 
To study the dominant negative effect hypothesized to be exerted by TRPS1 
proteins with missense mutations in the GATA zinc finger, transgenic mice 
were generated. The transgene contained the entire coding region of the 
human TRPS1 gene and carried a missense mutation at position 2701 that 
leads to the amino acid substitution threonin (T) to proline (P) at position 
901 in the GATA zinc finger (Fig. 8A). The human TRPS1 cDNA was 
preferred to the mouse Trps1 cDNA for the generation of the transgene, 
because the few differences with the mouse ORF sequence (~9%) allowed 
the discrimination and the estimation of the transgene expression rate by 
sequencing analysis. The A2701C mutation was found in a patient with 
TRPS type III (Vilain et al., 1999). The transgene was cloned into the 
pNASSßCol2a1 that contains the promoter and enhancer of the mouse 
Col2a1 gene able to drive the expression only in chondrocytes (Ueta et al., 
2001). Germline transmission was documented in four of the founder 
animals by Southern blot analysis digesting the genomic DNA with BamHI 
(probe shown in Fig. 8A; blot of the founder of line 2, Fig. 8B) and by their 
propagation four transgenic mice lines were established. The band pattern 
obtained by Southern blot analysis for the founder of line 2 showed a single 
integration site with the formation of a head-to-tail array given by two, 
maximum three copies of the transgene. In fact BamHI cuts once in each of 
the transgene constructs and yields a band of the same length as the 
injected fragment and a “junction fragment” containing genomic sequence. 
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E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 Generation of TRPS1 transgenic mice and verification of the transgene 
expression. A, Organization of the transgene and location of the primers used for 
the PCR strategies performed to analyze the transgene expression. The location of 
the hybridization probe used for the Southern blot experiments is also shown. B, 
Southern blot analysis performed to detect the founder of line 2 (lane 10), by 
digesting the genomic DNA with BamHI. C, Southern blot analysis of genomic DNA. 
Fragments corresponding to the mouse endogenous Trps1 and to the human 
transgene are shown. Lanes 3,4,5,12 represent wt mice; lanes 2,7,8,10 represent 
tg mice and lanes 1,6,9,11 represent tgtg mice. D, 1^ PCR strategy for the 
assessment of the transgene expression. In lanes 2-10 it is possible to detect the 
properly processed human mutant TRPS1 mRNA (tg embryos). Lane 1 represents a 
wt mouse and lane 11 corresponds to the construct used for the injection. E, 
Sequences obtained after the 2^ PCR strategy. The differences between the mouse 
Trps1 and the human TRPS1 sequences are highlighted by colored bars. In the wild 
type embryo only the mouse Trps1 mRNA is detectable. In the tg and tgtg embryos 
are visible both the endogenous mouse Trps1 mRNA and the mutant human TRPS1 
mRNA. Note the variation in transgene’s expression between tg and tgtg embryos.  
M: DNA marker 
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3.3.2  Assessment of transgene expression 
 
The expression of the transgene was proved for the four mouse lines by RT-
PCR using RNA extracted from the limbs of 12.5 days old embryos (E12.5), 
because Trps1 is high expressed at this stage of limb development (Kunath 
et al., 2002). The expression of Col2a1 at this stage was proved as well 
(data not shown). After the reverse transcription, two different PCR 
strategies were chosen to detect the transgene expression (Fig 8A). By 
using primers flanking the ß-globin intron present in the transgene (the 
forward primer annealed in the Col2a1 promoter and the reverse primer in 
TRPS1 exon 3), it was possible to amplify only the transgene sequence and 
in transgene-expressing embryos its proper spliced products (1^PCR 
strategy, fig. 8D). In all the embryos identified as transgenic by Southern 
blot, the properly processed human mutant TRPS1 mRNA was detected by 
PCR. 
The human TRPS1 and the mouse Trps1 ORF sequences show a 91,3% 
identity. The nucleotide differences are spread over the entire sequences 
(excluding the zinc finger domain sequences, which are conserved between 
human and mouse). The 2^PCR strategy used primers chosen in a region 
identical between human and mouse sequence and they amplified the 
region containing the GATA domain with the missense mutation. The PCR 
products were sequenced and the few variations present between mouse 
and human allowed the simultaneous detection of both the endogenous 
mouse Trps1 mRNA and the mutant human TRPS1 mRNA (Fig. 8E). 
The four lines of transgenic mice present different degrees of transgene 
expression and the transgenic mice from line 2 were those with the highest 
rate of expression. To increase the expression of the human transgene mice 
homozygous for the transgene (tgtg animals) were generated by breeding 
two transgenic mice from line 2. Fig. 8C shows a Southern blot of genomic 
DNA of wt, tg and tgtg animals. In Fig. 8E an example of sequences, which 
were obtained after RT-PCR performed on RNA extracted from E12.5 limbs 
of wild type, tg and tgtg embryos is shown. Although sequencing is not a 
precise quantitative method, looking at several sequences of tgtg embryos, 
it was possible to detect a slight but certain increase of the transgene 
expression in comparison to the tg embryos. 
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3.3.3  Gross phenotype and skeletal morphology 
 
Neither the heterozygous nor the homozygous transgenic mice showed 
visible differences in their phenotype when compared with the wild type 
animals. To visualize and consequently better analyze the skeletal 
morphology of the transgenic mice, the whole skeletons of E16.5 embryos 
and 4-week old mice were stained with alcian-blue and alizarin red. No 
visible deformations in the skeleton of transgenic mice compared with that 
of wild type animals were detected (Fig. 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A       wt 1                             tgtg 1             B        wt 2                             tgtg 2 
   C          wt 2                                     tgtg   2  
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Fig. 9 Alizarin red- and alcian-blue-stained skeletal preparation of four sib E16.5 
mouse embryos, wt1, wt2, tgtg1 and tgtg2, and two sib 4-week old mice, wt3 and 
tgtg3. A, Ventral view of wt1 and tgtg1. B, Lateral view of wt2 and tgtg2. C, Spinal 
column and hindlimbs view of wt2 and tgtg2. D, Dorsal view of wt3 and tgtg3. E, 
Lateral view of wt3 and tgtg3. F, Spinal column and hindlimbs of wt3 and tgtg3.  
Red staining represents the bone and blue staining represents the cartilage. 
 
 
 
 
    D                                                          E 
        wt3                   tgtg3                        
F     wt3                          tgtg3 
 
wt3 
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3.3.4  In situ hybridization 
 
To examine possible defects in the differentiation process of the cartilage in 
the transgenic animals, in situ hybridization analyses were performed in 
collaboration with the group of Andrea Vortkamp (Institut für 
Molekulargenetik, Max-Planck-Institut, Berlin). Additionally, the forelimbs of 
wild type and transgenic animals (tg and tgtg) were stained with Safranin 
which allowed to detect the chondrocytes organization in the limb’s growth 
plates (Fig. 10). The expression pattern of several genes known to be 
involved in limb development were analyzed, like Ihh (Indian hedgehog), 
PTHrP (Parathyroid hormone-like peptide), ColII (type II collagen), ColX, 
(type X collagen), Mmp13 (Matrix metalloproteinase 13) and Ptch (Patched) 
(Table 4) in forelimbs of E14.5, E16.5 and E18.5 wild type embryos (wt), 
transgenic embryos (tg) and embryos homozygous for the transgene 
(tgtg). The results obtained for Ihh, ColX and Trps1 are shown in Fig. 11.  
 
 
 gene expression pattern in cartilage and 
skeletal elements of mouse limbs 
ColII proliferating chondrocytes 
ColX hypertrophic chondrocytes 
Ihh prehypertrophic chondrocytes 
PTHrP 
 
joint regions, periarticular 
chondrocytes 
Ptch 
 
between proliferating and 
prehypertrophic chondrocytes 
 
Mmp13 late hypertrophic chondrocytes 
Trps1 
 
joint regions, periarticular 
chondrocytes, prehypertrophic 
chondrocytes 
 
Table 4 Expression pattern of the genes used for the in situ hybridization in cartilage  
 
and skeletal elements of mouse limbs 
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Fig. 11-continued 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several mice from different litters were analyzed but at these stages of 
limbs development (E14.5, E16.5 and E18.5) reliable variations in the 
expression patterns of the genes used for the in situ hybridization were not 
detected. 
 
                           Trps1 
 
    wt                       tg                    tgtg 
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3.4    cDNA microarray analysis of mouse embryonic tissues 
 
In order to identify potential targets of Trps1, expression profiles of the 
limbs and snouts of Trps1∆GATA-Znf/∆GATA-Znf and Trps1+/∆GATA-Znf mouse 
embryos (Malik et al., 2002) were compared with those of wild type 
embryos. Affymetrix MOE430A oligonucleotide arrays, containing about 
22000 probe sets, were used to this purpose. Genes were defined as up- or 
downregulated, respectively, when their expression levels were at least 1.5 
fold increased or decreased in the mutant mice with a standard deviation 
among the replicates of less than 25%. Moreover, genes were considered 
differentially expressed when in the replicates of one genotype at least two 
were scored as „absent“ and the calls in the other genotype were scored as 
„present“ in all samples. In this case, we defined the fold change as >1.5 
for the upregulated genes and <-1.5 for the downregulated genes.  
Some of the analyzed genes were represented by several sets on the array 
chip. Only the sets with the highest fold change were considered. 
  
 
3.4.1  cDNA microarray analysis of mouse embryonic limbs 
 
Expression profiles of the limbs of three wild type mouse embryos were 
compared with those of the limbs of two Trps1+/∆GATA-Znf and three 
Trps1∆GATA-Znf/∆GATA-Znf mouse embryos from the same litter at E11.5. Five 
hundred forty-nine genes fulfilled all criteria, listed above, and they were 
considered as abnormally expressed in the mutants (Table 5).  
The highest fold change in the mean expression values was found 
comparing the expression profiles of the heterozygotes with those of the 
wild type. The genes Extl2 (exotoses multiple-like 2) and Matn2 (matrilin 2) 
were 2.1-fold upregulated in the heterozygotes and the gene Shoc2 (soc-2, 
suppressor of clear homolog) was 2.1-fold downregulated in the 
heterozygotes.  
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Table 5 Number of differentially expressed genes in the expression profiles of the 
limbs of mutant embryos in comparison with those of the limbs of wild type 
embryos. -/-:  Trps1∆GATA-Znf/∆GATA-Znf mice.  +/-: Trps1+/∆GATA-Znf mice. 
 
 
 
 
 
 
 
 
 
Fig. 12 shows a functional classification of the genes found to be 
upregulated and downregulated, respectively. Most of the differentially 
expressed genes were involved in signal transduction, in cell growth and in 
transcription.  
 
 
                                                     A  Upregulated genes           B Downregulated genes  
Gene products involved in: 
 
A.  transcription 
B.  signal transduction  
C.  metabolism    
D.  transport   
E.  cell growth, division, 
defense  and death 
F.  acid nucleic metabolism 
G.  protein conformation,    
     synthesis and degradation 
H.  cell organization 
I.  unknown (ESTs)     
 
 
 
Fig. 12 Functional classification of the genes differentially expressed in the limbs of 
mutant mice. The Y-axis represents the percentage of genes.                          
-/-:  Trps1∆GATA-Znf/∆GATA-Znf mice.  +/-: Trps1+/∆GATA-Znf mice. 
 
 
Thirty-six genes showed the same tendency of regulation in both wild type-
homozygous and wild type-heterozygous comparisons. They are listed and 
shortly described in Tables 6 (upregulated) and Table 7 (downregulated). 
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Table 6 Genes upregulated in limbs of both Trps1∆GATA-Znf/∆GATA-Znf and Trps1+/∆GATA-
Znf, when compared to the wild type.  
-/-:  Trps1∆GATA-Znf/∆GATA-Znf mice.   +/-: Trps1+/∆GATA-Znf mice. 
 
Gene upregulated 
Gene 
GenBank accession number -/- 
Fold change 
+/- 
Fold change 
 
(hypothetical) 
function 
 
Arf3  
ADP-ribosylation factor 3 
NM_007478 
1.5 1.5 
 
Transport 
Laptm4b  
lysosomal-associated protein 
transmembrane 4B 
NM_033521 
 
1.8 
 
1.5 
 
Cell growth, division,  
defense and death 
 
Arntl 
aryl hydrocarbon receptor nuclear 
translocator-like 
NM_007489 
 
1.5 
 
1.8 
 
Transcription 
Extl2 
Mus musculus exotoses (multiple)-like 
2 
NM_021388 
 
 
1.5 
 
 
2.1 
 
Cell organization 
B4galt6  
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6 
NM_019737 
 
>1.5 
 
>1.5 
 
Metabolism 
Setdb1 
SET domain, bifurcated 1 
C77070 
 
>1.5 
 
>1.5 
 
Unknown 
Cstf1 
cleavage stimulation factor, 3' pre-
RNA, subunit 1 
NM_024199 
 
>1.5 
 
>1.5 
 
Acid nucleic 
metabolism 
Akt3  
human protein kinase Bgamma 
NM_011785 
 
>1.5 
 
>1.5 
 
Signal transduction 
Exosc1 
exosome component 1 
NM_011785 
 
>1.5 
 
>1.5 
Protein conformation,  
synthesis and 
degradation 
Rnf-37 
ring finger protein 37NM_080562  
 
>1.5 
 
>1.5 
 
Transcription 
expressed sequence AI428936  
NM_153577   
 
>1.5 
 
>1.5 
 
Unknown 
expressed sequence 
NM_175127 
>1.5 >1.5 Unknown 
Sod2 
superoxide dismutase 2, mitochondrial  
NM_013671  
 
>1.5 
 
>1.5 
 
Metabolism 
Dab1 
disabled homolog 1 NM_010014  
 
>1.5 
 
>1.5 
Signal transduction 
cDNA clone 
BG965874 
1.9 2.0 Unknown 
Cyp4f16 
cytochrome P450, family 4, subfamily 
f, polypept.16  
NM_024442 
 
1.7 
 
1.8 
 
Signal transduction 
DC6 protein  
NM_175009  
 
1.7 1.6 Unknown 
cDNA cone 
BE628832  
 
1.6 1.5 Unknown 
cDNA clone 
NM_028242 
 
1.9 1.6 Unknown 
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Table 7 Genes downregulated in limbs of both Trps1∆GATA-Znf/∆GATA-Znf and 
Trps1+/∆GATA-Znf mice, when compared to the wild type mice. -/-:  Trps1∆GATA-Znf/∆GATA-
Znf mice.   +/-: Trps1+/∆GATA-Znf mice. 
 
Gene downregulated 
 
Gene 
GenBank accession number 
 -/- 
Fold change 
+/- 
Fold change 
 
(hypothetical) 
function 
 
 
Ywhaz 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, zeta polypeptide  
NM_011740 
 
-1.8 
 
-1.6 
 
 
Cell growth, division,  
defense and death 
 
Emp3  
epithelial  
membrane protein 3 
NM_010129 
-1.8 -1.6 
 
 
Cell growth, division,  
defense and death 
 
Mt1a  
metallothionein-I activator 
NM_023127 
 
-1.7 
 
-1.8 
 
Transcription 
cDNA clone 
 NM_026846  
 
<-1.5 
 
<-1.5 
 
Unknown 
Tm4sf7 
 transmembrane 4 superfamily 
member 7 NM_053082 
 
<-1.5 
 
<-1.5 
 
Unknown 
Ncf2 
neutrophil  
cytosolic factor 2  
NM_010877 
 
<-1.5 
 
<-1.5 
 
Metabolism 
Eng 
Endoglin 
NM_007932 
 
<-1.5 
 
<-1.5 
 
Signal transduction 
Pik3cg 
phosphoinositide-3-kinase, 
 catalytic, gamma polypeptide 
NM_020272 
 
<-1.5 
 
<-1.5 
 
Signal transduction 
LynB 
Mouse lyn B protein tyrosine 
kinase 
NM_010747 
 
<-1.5 
 
<-1.5 
 
Signal transduction 
Gadd45g 
growth arrest and DNA-damage-
inducible 45 gamma 
NM_011817 
 
 
<-1.5 
 
 
<-1.5 
 
Cell growth, division,  
defense and death 
 
Tsix 
 X (inactive)-specific transcript 
AF138745.1 
 
 
<-1.5 
 
<-1.5 
 
Unknown 
 
cDNA clone 
BG069250  
 
<-1.5 <-1.5 Unknown 
cDNA clone 
BC022145.1  
 
<-1.5 <-1.5 Unknown 
cDNA clone 
BC025863.1  
 
<-1.5 <-1.5 Unknown 
F11r 
F11 receptor  
NM_172647   
<-1.5 <-1.5 
 
Signal transduction 
Ptdss2 
phosphatidylserine synthase 2 
NM_013782 
 
 
<-1.5 
 
<-1.5 
 
Metabolism 
cDNA clone 
AA185884  
 
<-1.5 <-1.5 Unknown 
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3.4.1.1 The relative expression of several genes was 
confirmed by real-time PCR experiments 
 
The relative gene expression for a subset of differentially expressed genes 
was assessed using real-time PCR as an independent method for validating 
the microarray data. RNA was isolated from the limbs of sixteen E11.5 
mouse embryos (two wild type, six Trps1∆GATA-Znf/∆GATA-Znf and eight 
Trps1+/∆GATA-Znf animals). They derived from four different litters, different 
from the ones used for the microarray hybridization. A short description of 
the 12 genes and their fold expression changes by microarray and real-time 
PCR are summarized in Table 8. The overall tendency of changes was 
confirmed for seven genes: Emp3, Laptm4B, Hoxb8, Hspg2 and Lamb1-1 
and partially (only for the Trps1∆GATA-Znf/∆GATA-Znf mice) for Gadd45g and Eng. 
In Fig. 13 the detailed real-time PCR results for the confirmed differentially 
expressed genes are shown. 
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Fig. 13 Real-time PCR results for the seven genes whose relative expression 
changes confirmed the microarray data. Each point represents the values for a 
single embryo. The values are the averages of at least two independent 
experiments. +/+: wild type mice. -/-:  Trps1∆GATA-Znf/∆GATA-Znf mice. 
 +/-: Trps1+/∆GATA-Znf mice. n.d.: not done. 
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3.4.1.2  TRPS1 actively represses the HSPG2 promoter activity 
 
Since TRPS1 is known to repress GATA-dependent gene activation, those 
genes, whose promoter regions were already characterized and contained 
GATA consensus sequences, were considered for further analyses. The 
functional activity of the human HSPG2 promoter (~ 2.5 kb of the 5’-
flanking region) was previously assessed in HeLa cells (Iozzo et al, 1997) 
and it contained nine GATA-1 motifs. To analyze whether TRPS1 could 
directly influence the HSPG2 promoter activity, a luciferase reporter gene 
assay was set up. The 1711 bp from the HSPG2 promoter region (see 
appendix for GenBank Accession number and for primer sequences) were 
amplified and inserted into the reporter plasmid containing the luciferase 
cDNA, upstream of the SV40 promoter, to obtain HSPG2-SV40. The 
luciferase activity of HeLa cells transfected with HSPG2-SV40 was arbitrarily 
set as 1.0 fold activation (Fig. 14, column 3). Control transfections could 
exclude a significant increase of the SV40 reporter plasmid activity in the 
presence of the HSPG2 promoter elements (Fig. 14, columns 1 and 3) and 
an effect of TRPS1 on the SV40 promoter alone (Fig. 14, column 2). Co-
transfection with TRPS1 led to a dosage-dependent reduction of the 
HSPG2-SV40 reporter plasmid activity up to 2 folds (Fig. 14, columns 4 and 
5). On the contrary, only a slight repression of the reporter plasmid activity 
took place when the cells were transfected with T901P (Fig. 14, column 6), 
that is a mutated form of TRPS1 with a missense mutation in the GATA Znf-
encoding region. The transcriptional repression of TRPS1 was not 
compromised by the co-transfection of the cells with GATA4 factor (Fig. 14, 
column 7), that, even alone, had no significant influence on the reporter 
plasmid HSPG2-SV40 (Fig. 14, column 8). These results could be confirmed 
also in COS7 cells (data not shown). 
 
In summary, these findings indicated that TRPS1 was able to actively 
repress the transcription of HSPG2. 
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Fig. 14 Luciferase reporter gene assay in HeLa cells. HeLa cells were transiently 
transfected with plasmids encoding the HSPG2-SV40 reporter (0.5 µg), the SV40 
plasmid (0.5 µg), the TRPS1 transcription factor (1 or 0.5 µg), the mutated form of 
TRPS1 transcription factor, T901P (1 µg) and the XGATA4 transcription factor (1 µg). 
The results are representative of at least two independent experiments.  
The Y-axis represents the fold activation 
 
 
 
 
 
HSPG2-SV40  0.5   
 
TRPS1                    -         1        -       1   0.5       -        1         - 
 
T901P                    -         -         -       -    -          1        -         - 
 
XGATA4                 -         -         -        -    -          -        1        1 
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3.4.2 cDNA microarray analysis of mouse embryonic snouts 
 
Snout RNAs obtained from three wild type mouse embryos, three Trps1∆GATA-
Znf/∆GATA-Znf and three Trps1+/∆GATA-Znf mouse embryos, from the same litter at 
E12.5, were hybridized to the Affymetrix MOE430A cDNA microarray. The 
expression profiles of the mutant animals were then compared with those of 
the wild type animals. According with the criteria pointed out in section 3.4, 
715 differentially expressed genes were identified in the mutant embryos 
(Table 9). The highest fold change in the mean expression values was found 
comparing the expression profiles of the Trps1∆GATA-Znf/∆GATA-Znf mice with those 
of the wild type mice. The gene Rnpc2 (RNA-binding region (RNP1, RRM) 
containing 2) was 2.6 fold upregulated in the Trps1∆GATA-Znf/∆GATA-Znf.  
 
Table 9 Number of differentially expressed genes in the expression profiles of the 
snouts of mutant embryos in comparison with those of the snouts of wild type 
embryos. -/-:  Trps1∆GATA-Znf/∆GATA-Znf mice.  +/-: Trps1+/∆GATA-Znf mice. 
 
 
 
 
A functional classification of the abnormally expressed genes showed that 
many of these genes were involved in signal transduction and in transcription 
regulation (Fig. 15). Interestingly, among them, several genes whose loss-
of-function mutations were already known to cause craniofacial defects in 
mice were identified (Wilkie et al., 2001) (Tables 10 and 11). The 61 genes 
that showed the same tendency of regulation in both wild type- Trps1∆GATA-
Znf/∆GATA-Znf and wild type-Trps1+/∆GATA-Znf comparison are listed and shortly 
described in Tables 12 (downregulated) and Table 13 (upregulated). 
 
 
UPREGULATED DOWNREGULATED 
 
-/- 
 
 
+/- 
 
 
-/- 
 
 
+/- 
 
212 128 128 247 
total 340 total 375 
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                                                          A upregulated genes                           B downregulated genes 
 
A.  transcription 
B.  signal transduction  
C.  metabolism    
D.  transport   
E.  cell growth, division, defense  
     and death 
F.  acid nucleic metabolism 
G.  protein conformation,    
     synthesis and degradation 
H.  cell organization 
I.  unknown (ESTs)     
 
 
 
Fig. 15 Functional classification of the genes differentially expressed in the snouts of 
mutant mice. The Y-axis represents the percentage of genes.  -/-: Trps1∆GATA-Znf/∆GATA-
Znf mice. +/-:Trps1+/∆GATA-Znf mice. 
 
Table 10 Genes upregulated in Trps1∆GATA-Znf/∆GATA-Znf mice whose loss-of-function 
mutations cause craniofacial defects in mice. 
-/-: Trps1∆GATA-Znf/∆GATA-Znf mice. +/-:Trps1+/∆GATA-Znf mice. 
 
 
 
 
 
 
fold change  
upregulation 
microarray 
 
Gene 
 
Protein 
Major defects 
(time when defects first 
show) 
Primary 
abnormality  
-/- +/- 
Dlx1 
 
Distal-less homeobox 1 
 
Abnormal ala temporalis, 
minor abnormalities of some 
other bones, small cleft 
palate in 10% of cases (-) 
 
- 1.5 1.1 
Pax6 
 
Paired box 6 
 
Homozygote:absent eyes and 
nasal cavities. Heterozygote: 
small eyes, iris hypoplasia 
(E10.5) 
 
Aberrant lens and 
nasal placode 
formation, delayed 
closure of optic 
fissure 
1.6 
absent 
in +/- 
0
5
10
15
20
25
30
35
40
45
A   B   C   D   E   F   G   H   I   
0
5
10
15
20
25
30
35
40
A   B   C   D   E   F   G   H   I 
-/- +/- 
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Table 11 Genes downregulated in Trps1 mutant mice whose loss-of-function 
mutations cause craniofacial defects in mice.  
-/-: Trps1∆GATA-Znf/∆GATA-Znf mice. +/-:Trps1+/∆GATA-Znf mice. 
 
 
 
 
 
 
 
 
 
fold change 
downregulation 
microarray 
 
 
 
Gene 
 
Protein 
 
 
Major defects 
(time when defects first 
show) 
 
Primary 
abnormality  
-/- +/- 
 
Col2a1 
Procollagen, type 
II, α1 
 
Bulging forehead, short snout, 
cleft palate (E13) 
Defective endochondral 
bone formation 
-1.6 -1.6 
 
Dlx5 
Distal-less 
homeobox 5 
 
28% exencephaly, 
hypomineralized 
parietal/interparietal bones, 
abnormal nasal and otic capsules, 
branchial arches, 88% cleft 
palate, malformed teeth (E9.5) 
- -1.1 -1.6 
 
Gli2 
GLI-Kruppel family 
member 2 
 
Deficient medial ossification of 
frontal and parietal bones, 
upper/lower incisors, cleft palate 
(64%) (E10.5) 
 
Skeletal development -1.2 -1.6 
Hhex 
Hematopoietically 
expressed 
homeobox 
 
Variable anterior truncations 
(E8.5) 
Required for 
specification of axial 
mesendoderm 
<-1.5 1.0 
Pdgfra 
Platelet-derived 
growth factor 
receptor,   α-poly-
peptide 
 
Cleft face, bleb over neural tube 
(E8) 
Failure of subset of non-
neural-crest cells to 
migrate 
-1.3 -1.8 
Prrx1 
Paired-related 
homeobox 1 
Cleft secondary palate, absent 
squamosal, zygomatic , tympanic 
ring, hypoplastic mandible 
(E13.5) 
Defective growth of 
mandibular arch 
components 
-1.7 -1.9 
 
Trp53 
transformation-
related protein 53 
(p53) 
 
 
8-16% exencephaly 
 
- 
 
<-1.5 
 
<-1.5 
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Table 12 Genes upregulated in snouts of both Trps1∆GATA-Znf/∆GATA-Znf and Trps1+/∆GATA-
Znf mice, when compared with the wild type mice.  
-/-: Trps1∆GATA-Znf/∆GATA-Znf mice. +/-:Trps1+/∆GATA-Znf mice. 
 
 
Gene upregulated 
 
 
Gene 
GenBank accession 
number 
 
 
-/- 
Fold change 
+/- 
Fold change 
(hypothetical) function 
 
cDNA clone 
AI645547  
>1.5 >1.5 Unknown 
Lactb  
lactamase, beta 
NM_030717.1  
 
>1.5 >1.5 Signal transduction 
cDNA clone 
BB536931 
 
>1.5 >1.5 Unknown 
Ppp1r14b  
protein phosphatase 
1, regulatory 
(inhibitor) subunit 14B 
BM941586 
 
>1.5 >1.5 Signal transduction 
cDNA clone 
BC017633.1 
 
>1.5 >1.5 Unknown 
cDNA clone 
BM217857 
 
>1.5 >1.5 Unknown 
Pkp4 
plakophilin 4 
AW764208 
>1.5 >1.5 Unknown 
D16Wsu73e 
DNA segment, Chr 16, 
Wayne State 
University 73, 
expressed 
BB751546 
 
>1.5 >1.5 Unknown 
cDNA clone 
BE992311 
 
>1.5 >1.5 Transcription 
Zwint 
ZW10 interactor 
BC013559.1 
 
>1.5 >1.5 Unknown 
ESTs, Moderately 
similar to ubiquitin A-
52 residue ribosomal 
protein fusion product 
1 
AU043470 
>1.5 >1.5 Unknown 
Sytl3 
synaptotagmin-like 3 
AB050743.1 
 
>1.5 >1.5 Signal transduction 
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Table 12-continued 
Gene upregulated 
 
 
Gene 
GenBank accession 
number 
 
Homozygotes 
Fold change 
 
Heterozygotes 
Fold change 
 
 
(hypothetical) function 
 
Ywhaz   
tyrosine 3-
monooxygenasetryptophan 
5-monooxygenase activation 
protein, zeta polypeptide 
BF608615 
2.3 
 
1.9 Signal transduction 
Laptm4b  
lysosomal-associated protein 
transmembrane 4B 
BB560429 
1.8 
 
1.9 
Cell growth, division and 
death 
 
Rpl41 
ribosomal protein L41 
BI694945 
1.9 1.6 
Protein 
conformation,synthesis, 
degradation 
 
Hnrpa1  
heterogeneous nuclear 
ribonucleoprotein A1 
BE685966 
1.9 1.8 Acid nucleic metabolism 
cDNA clone 
BM235840 
1.8 1.5 
Unknown 
 
Lap3   
leucine aminopeptidase 3  
AI875680 
1.7 1.6 
Protein 
conformation,synthesis, 
degradation 
 
Snx6 
sorting nexin 6 
BC025911.1 
1.6 1.6 Transport 
D4Wsu53e 
DNA segment, Chr 4, Wayne 
State University 53, 
expressed  
NM_023665.1 
1.6 1.5 Unknown 
HnRNP A1  
Heterogeneous nuclear 
ribonucleoprotein A1 
BE685966 
1.5 1.5 Acid nucleic metabolism  
Nov  
nephroblastoma 
overexpressed  
X96585.1 
1.5 1.9 
Cell growth, division and 
death 
 
Ankib 
ankyrin repeat and IBR 
domain containing 1 
C80642 
 
>1.5 >1.5 
Transcription 
 
similar to heterogeneous 
nuclear ribonucleoprotein A3 
BB723867 
 
>1.5 >1.5 Unknown 
cDNA clone 
BC020137.1 
 
>1.5 >1.5 Unknown 
cDNA clone 
AV271161 
>1.5 >1.5 Unknown 
Calm3  
calmodulin 3 
AV047570 
>1.5 >1.5 
Cell growth, division and 
death 
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Table 13 Genes downregulated in snouts of both Trps1∆GATA-Znf/∆GATA-Znf and 
Trps1+/∆GATA-Znf mice, when compared with the wild type mice. -/-: Trps1∆GATA-Znf/∆GATA-
Znf mice. +/-:Trps1+/∆GATA-Znf mice. 
Gene downregulated 
Gene 
GenBank accession number 
 
-/- 
Fold change 
 
+/- 
Fold change 
 
(hypothetical) 
function 
Golga3 
golgi autoantigen, golgin 
subfamily a,3 
BI693873 
 
<-1.5 
 
<-1.5 
 
Signal transduction 
Sema4a s 
semaphorin 4A 
NM_013658.1 
 
 
<-1.5 
 
<-1.5 
 
 
Signal transduction 
St7  
suppression of tumorigenicity 7 
NM_022332.1 
<-1.5 <-1.5 Signal transduction 
V1rc5  
vomeronasal 1 receptor, C5  
NM_053235.1 
<-1.5 <-1.5 Signal transduction 
Zfp36l2  
zinc finger protein 36, C3H type-
like 2 
BG094962 
<-1.5 <-1.5 Unknown 
Aqp4  
aquaporin 4 
BB193413 
<-1.5 <-1.5 Transport 
Zfp261  
zinc finger protein 261 
AV370364 
<-1.5 <-1.5 Unknown 
Rusc1  
RUN and SH3 domain containing1 
BB806780 
<-1.5 <-1.5 Unknown 
Slc16a2  
solute carrier family 16 
(monocarboxylic acid 
transporters), member 2  
AW105741 
<-1.5 <-1.5 Transport 
Mafb 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein B (avian) 
AW412521 
<-1.5 <-1.5 Transcription 
Cacng5  
calcium channel, voltage-
dependent, gamma subunit 5 
AF458900.1 
<-1.5 <-1.5 Transport 
expressed sequence 
AW557946 
<-1.5 <-1.5 Unknown 
Matn4 
matrilin 4  
NM_013592.1 
<-1.5 <-1.5 Cell organization 
Trp53  
transformation related protein 53 
BB828014 
<-1.5 <-1.5 Transcription 
cDNA clone 
BB350484 
<-1.5 -1.7 Unknown 
cDNA clone 
AK014318.1 
<-1.5 <-1.5 Unknown 
Fzd6  
frizzled homolog 6 
NM_008056.1 
<-1.5 <-1.5 Signal transduction 
Tgfbr2 
transforming growth factor, beta 
receptor II 
BG793483 
<-1.5 <-1.5 Signal transduction 
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Table 13-continued 
 
 
Gene downregulated  
Gene 
GenBank accession number 
 
 
-/- 
Fold change 
 
+/- 
Fold change 
 
(hypothetical) function 
 
Ywhaz   
tyrosine 3-
monooxygenasetryptophan 5-
monooxygenase activation 
protein, zeta polypeptide 
NM_011740 
-2.1 
 
-1.9 
 
Cell growth, division,  
defense and death 
 
cDNA sequence  
BB770932 
 
-1.8 -1.5 Unknown 
Dnm  
dynamin 
L29457.1 
-1.7 -1.6 Signal transduction 
Prrx1 
paired-related homeobox  
gene 1 
-1.7 -1.9 Transcription 
Col2a1  
procollagen, type II, alpha  
NM_031163.1 
-1.6 
-1.6 
 
Cell organization 
Top2b  
topoisomerase (DNA) II beta 
BB166592 
-1.6 -1.9 Acid nucleic metabolism 
Col9a1  
procollagen, type IX, alpha 1 
AK004383.1 
-1.5 -1.5 Cell organization 
Pdlim4  
PDZ and LIM domain 4 
NM_019417.1 
<-1.5 <-1.5 Signal transduction 
Opn1sw  
opsin 1 (cone pigments), 
short-wave-sensitive (color 
blindness, tritan) 
BC026021.1 
<-1.5 <-1.5 Signal transduction 
Mint   
Msx2 interacting nuclear target 
protein 
NM_019763.1 
<-1.5 <-1.5 Transcription 
Oprk1  
opioid receptor, kappa 1 
L11065.1 
<-1.5 <-1.5 Signal transduction 
Ott   
ovary testis transcribed 
X96606.1 
<-1.5 <-1.5 Unknown 
Aqr   
aquarius 
AK020468.1 
<-1.5 <-1.5 Unknown 
Bcl2l11 
BCL2-like 11 
BB667581 
 
<-1.5 <-1.5 
Cell growth, division,  
defense and death 
 
Similar to vesicle amine 
transport protein 1 
BB559097 
<-1.5 <-1.5 Unknown 
Mid2  
midline2  
AF196480.1 
<-1.5 <-1.5 
Cell growth, division,  
defense and death 
 
cDNA clone 
BB133120 
<-1.5 <-1.5 Unknown 
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3.4.2.1 The relative expression of three genes was confirmed by 
real-time PCR experiments 
 
Six abnormally expressed genes (Laptm4b, Nov, Prrx1, Col2a1, Col9a1 and 
Fzd6) were chosen for validation by real-time PCR analysis.  We used RNAs 
isolated from the snout of fifteen E12.5 mouse embryos (four wild type, five 
Trps1∆GATA-Znf/∆GATA-Znf and six Trps1+/∆GATA-Znf mice) originating from three 
litters, different from the ones used for the microarray hybridization. The 
differential expressions of mRNAs encoding Laptm4b, Nov and Fzd6 (only for 
the homozygotes) were confirmed (Table 14).  
 
Table 14 Differentially expressed genes selected for the real-time PCR validation. 
The genes whose direction of the relative fold change is concordant with the 
microarray data are shown in red. -/-: Trps1∆GATA-Znf/∆GATA-Znf mice. +/-:Trps1+/∆GATA-Znf 
mice. ECM: extracellular matrix 
 
 
 
 
relative expression 
microarray real-time PCR gene 
(hypothetical) 
function 
reason for real-time PCR 
validation 
 
+/- 
 
-/- +/- -/- 
 
Laptm4b 
lysosomal-
associated 
protein 
transmembrane 
 
 
Cell growth, 
division, 
defense and  
death 
 
the only gene upregulated 
in the limb and snout 
knockout mice, in both 
+/- and -/- 
 
1.5 2.3 1.4 1.6 
Nov 
nephroblastom 
overexpressed 
gene 
Cell growth, 
division, 
defense and  
death 
the human gene is localized 
in 8q24.1; upregulated in 
both +/- and -/- 
 
1.9 1.5 1.2 1.2 
 
Prrx1 
paired-related 
homeobox gene 1 
 
Transcription 
 
the knockout mice show 
malformation of craniofacial, 
appendicular and axial 
structures; downregulated in 
both +/- and -/- 
 
-1.9 
 
-1.7 
 
1.2 1.2 
 
Col2a1 
type II collagen, a1 
 
Structural molecule 
activity 
 
important component of the 
cartilage ECM; downregulated 
in both +/- and -/- 
 
 
-1.6 -1.6 1.2 1.9 
Col9a1 
type IX collagen, a1 
Structural molecule 
activity 
downregulated in both 
+/- and -/- 
 
-1.5 -1.5 1.1 1.5 
Fzd6 
frizzled 6 
Signal 
transduction 
important role in hair 
follicle; downregulated in 
both +/- and -/- 
 
<-1.5 <-1.5 1.2 -1.3 
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In Fig. 16 the detailed real-time PCR results for the confirmed differentially 
expressed genes are shown. 
 
 
 
Fig. 16 Real-time PCR results for the three genes whose relative expression changes 
validate the microarray data. Each point represents the values for a single embryo. 
The values are the averages of at least two independent experiments. +/+: wild type 
mice. -/-:  Trps1∆GATA-Znf/∆GATA-Znf mice. +/-: Trps1+/∆GATA-Znf mice. 
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3.4.2.2 TPRS1 actively represses the LAPTM4b promoter activity 
 
Laptm4b was the only gene found to be upregulated in the microarray data 
of E11.5 limbs and of E12.5 snouts in both Trps1+/∆GATA-Znf and Trps1∆GATA-
Znf/∆GATA-Znf mice. Moreover, its relative expression was confirmed by real time 
PCR experiments.  
The functional activity of the LAPTM4b promoter region (~ 1.5 kb of the 5’-
flanking region) was previously analyzed in hepatocellular carcinoma-related 
cell lines (Shao et al., 2003) and it contained two GATA-consensus motifs. To 
determine whether TRPS1 was able to directly affect the LAPTM4b promoter 
activity, a luciferase reporter gene assay was set up. Using specific primers, 
the LAPTM4b promoter was amplified and the 1532 bp PCR product (see 
appendix for GenBank Accession number and for primer sequences) was 
cloned into the pGL3b reporter plasmid (it does not contain any promoter) 
upstream to the luciferase cDNA, obtaining the LAPTM4b-pGL3b.  
In HeLa cells, the LAPTM4b promoter did not show any activity.  
Therefore, the reporter gene assays were carried out in COS7 cells, where 
the analyzed promoter was active and the luciferase activity of the cells 
transfected with the reporter plasmid LAPTM4b-pGL3b was set as 1.0 fold 
activation (Fig. 17, column 2). The pGL3b vector alone showed no activity 
(Fig. 17, column 1). When 1 µg of TRPS1-encoding plasmid was added the 
transcriptional activity of the reporter plasmid was repressed up to 50% (Fig. 
17, column 3). Further analyses are required to analyze the effect of mutant 
TRPS1 proteins and of XGATA factors on the LAPTM4b promoter activity. 
These findings demonstrated that LAPTM4b promoter activity can be directly 
repressed by TRPS1. 
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Fig. 17 Luciferase reporter gene assays in COS7 cells. The cells were transiently 
transfected with plasmids encoding the LAPTM4b-pGL3b reporter (0.5 µg) and the 
TRPS1 transcription factor (1 µg). As control the cells were transfected with the 
pGL3b alone (0.5 µg), which did not contain any promoter. The Y-axis represents the 
fold activation. 
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4.   DISCUSSION 
 
4.1   TRPS1 carries a single functional NLS  
 
By mutation analysis of TRPS type I patients, the single base exchange 
2854C>T was identified in the TRPS1 (see Results 3.1), which affected the last 
arginine residue of one of the two predicted NLS (RRRTRKR at position 946-
952 aa) of the TRPS1 transcription factor. Localization studies indicated that 
the single aa substitution R952C, prevents the TRPS1 from entering the 
nucleus (Kaiser et al., 2004).  
These findings highlighted the importance of the mutation analysis in TRPS 
patients to detect functional domains of the TRPS1 transcription factor. 
 
 
4.2  The TRPS1 transgenic mouse does not represent a model 
for TRPS III 
 
To study the pathogenesis of the severe TRPS type III, a transgene carrying 
the entire coding region of the human TRPS1 with the T901P missense 
mutation inserted in the GATA Znf, under the control of Col2a1 promoter, was 
used to generate a transgenic mouse model (see Results 3.3).  This specific 
mutation was chosen, because the affected patient defines the severe end of 
the TRPS spectrum (Vilain et al., 1999; Lüdecke et al., 2001). Probably, the 
T901P mutation leads to the disruption of the ß-sheet structure of this portion 
of the zinc finger and to the alteration of the shape of the entire zinc finger. 
Furthermore, current functional studies show that the mutant TRPS1 protein is 
able to antagonize the function of the TRPS1 wild type protein, not only 
through the abrogation of the TRPS1 repressional function, but even 
upregulating the GATA-mediated gene activation (Kaiser, pers. 
communication). The Col2a1 promoter and enhancer were selected to direct 
the expression of the transgene to chondrocytes in a developmental stage, in 
which the wild-type Trps1 is active (Ueta et al., 2001). This allows the analysis 
of the dominant negative effect exerted by the overexpression of a human 
mutated TRPS1 protein in the growth plates in the presence of two normal 
endogenous Trps1 copies.  
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Patients with TRPS usually display a progressive degeneration of their typical 
abnormal phenotype beginning from their childhood. Unexpectedly, even the 
4-week old transgenic mice did not show the TRPS typical brachydactyly or 
growth retardation (see Results 3.3.3).  
There are several explanations to account for the apparently normal phenotype 
of the transgenic mice. 
(I) By sequence analysis a surprisingly low transgene expression rate (~30%) 
was detected (see Results 3.3.2, Fig. 8E). If the amount of the mutant TRPS1 
transgene is not high enough, the quantity of co-regulators that it can recruit 
does not disturb the function of the endogenous Trps1, which carries on its 
normal regulatory functions. Ueta et al. (2001) used exactly the same Col2a1 
promoter/enhancer elements to overexpress Cbfa1 or its dominant negative 
form in chondrocytes, causing severe skeletal malformations in the mice. The 
difference of transgene expression between Cbfa1 and TRPS1 can be attributed 
to several factors, including differences in the chromosome position of the 
transgene integration site and copy number. In particular, expression from a 
transgenic locus may be silenced when repeated transgene copies are 
arranged as a concatameric array. Furthermore, chromatin structure at the 
site of integration can affect transgene expression, not only in plants (van 
Leeuwen et al., 2001), but in mammals as well (Garrick et al., 1998). 
(II) In the growth plates of the embryonic mouse limb, Col2a1 is highly 
expressed in resting and in proliferating chondrocytes and is less expressed in 
hypertrophic chondrocytes (Ueta et al., 2001; Olsen et al., 2000; Zhou et al., 
1995). Kunath et al. (2002) showed that Trps1 is highly expressed in the joint 
regions of the skeletal elements of the limbs, in the periarticular chondrocytes 
and in prehypertrophic chondrocytes of the growth plates of the limbs, during 
mouse embryonic development. Since the endochondral ossification is a very 
tightly regulated process, a slight difference of temporal and spatial expression 
of Col2a1 and Trps1 in the growth plates could prevent a dominant negative 
effect of the mutated TRPS1 protein.  
(III) The human mutated protein may not be recognized by the mouse protein 
complexes, which are involved in Trps1 regulatory activity and it is perhaps 
subject to the quality-surveillance mechanism and degraded (Clausen et al., 
2002). This hypothesis, however, is not very likely, considering that the only 
seven percent differences between the mouse and the human protein 
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sequences do not reside in the zinc finger regions, which are involved in 
protein-protein interactions. 
Highly sensitive studies like the in situ hybridization experiments (see Results 
3.3.4), which have been performed in limbs of transgenic mice at stages 
E14.5, E16.5 and E18.5, did not show any reliable differences in the 
expression pattern of genes like Ihh, PTHrP, ColII, ColX, MMP13 and PTCH.  
In addition to the explanations mentioned above, it is also possible that TRPS1 
does not interfere during endochondral ossification with the pathways in which 
those genes are involved. In fact, in the cDNA microarray analyses (see 
Results 3.4) performed later on tissues from the GATA-Znf deleted Trps1 
knockout mice, none of the genes used for the in situ hybridization, with the 
exception of ColII, was found to be differentially expressed in the mutant mice. 
 
 
4.3  Identification of the downstream genes of the TRPS1 
transcription factor 
 
A growing list of human diseases can be attributed to mutations in the genes 
coding for transcription factors (Latchman, 1996; Villard, 2004) causing 
disruption of biological pathways, which can lead to malformation, or 
tumorigenesis.  
Of great importance to disclose the physiological processes controlled by these 
transcription factors is the identification of their direct and indirect targets.  
Several methods can be used for this purpose. For example the combined use 
of siRNA-mediated gene silencing and cDNA microarray analysis can be useful 
to determine the effects of a gene knockdown in the cell (example Rb1, 
Semizarov et al., 2004).  
However, tissues or organs obtained from in vivo models such as knockout 
mice offer the best material to compare gene expression of the affected 
organism to that of the normal one, by using cDNA microarray analyses 
(example Pax6, Chauhan et al., 2002). 
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4.3.1  The silencing of the Trps1 transcription factor in NIH3T3 
might interfere with the control of cell cycle progression  
 
Fifty-nine genes were found to be abnormally expressed in NIH3T3 cells (29 
upregulated and 30 downregulated in treated cells) in which Trps1 expression 
was silenced as effect of transfection of siRNAs, homologous in sequence to 
the Trps1 gene (see Results 3.2.1). The NIH3T3 cell line was chosen for the 
RNA interference experiments for several reasons. First, Trps1 is highly 
expressed in these cells. Second, NIH3T3 can easily be transfected with siRNAs 
(Elbashir et al., 2001; Harborth et al., 2001). Third, functional analyses of 
TRPS1 have already been performed in human fibroblasts (Kaiser et al., 
2003a; Kaiser et al., 2003b).   
 
Some of the genes upregulated upon reduction of endogenous Trps1 level by 
siRNA transfection, thus normally repressed by Trps1, are involved in control 
of cell cycle progression.  
The Fos-like antigen 2, also called Fra2, is one of the four members of the Fos 
gene family. These genes encode leucine zipper proteins that can dimerize 
with proteins of the JUN family, thereby forming the transcription factor 
complex AP-1. As such, the FOS proteins have been implicated as regulators of 
cell proliferation, differentiation, and transformation (Review: Shaulian and 
Karin, 2001). In some cases, expression of the FOS gene has also been 
associated with apoptotic cell death (Ameyar et al., 2003). 
Bakiri et al. (2002) studied the functions of specific AP-1 dimers. The authors 
showed that NIH3T3 cells transiently transfected with cJun~Fra2 dimers (the 
tilde indicates a tethered dimer) were able to progress through S and G2/M 
phases of the cell cycle, while control cells stopped proliferating and 
accumulated in the Go/G1 compartments, in the presence of both increased cell 
density and serum withdrawal. This finding leads to the hypothesis that down 
regulation of c-Jun and Fra2 upon serum deprivation or cell-to-cell contact 
could therefore be a prerequisite for growth arrest (Lallemand et al., 1997).  
On the other hand, upregulation of FRA2 in chondrocytes due to a mutated 
TRPS1 could lead to an increased proliferation of normally resting 
chondrocytes and finally to premature closure of the growth plate. 
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Also the protein kinase, mitogen-activated, kinase 7 (named MKK7 or JNKK2) 
was found to be upregulated in the expression profiles of the treated NIH3T3 
cells. MKK7 belongs to the mitogen-activated protein kinase kinase (MAPKK) 
proteins and is a specific activator of JNK1 and JNK2 (Wu et al., 1997), which 
control a spectrum of cellular processes, including cell growth, differentiation, 
transformation, and apoptosis. Wada and Penninger (2004) demonstrated that 
MKK7 links stress signaling, among other to G2/M cell cycle progression and 
they discuss the importance of the MKK4 (another direct activator of 
JNK)/MKK7-JNK-c-Jun pathway linking stress and developmental signals to cell 
proliferation, cell cycle progression, cellular senescence, and apoptosis. 
 
p63 was also found to be upregulated in treated NIH3T3 cells. Together with 
p73, p63 is high homolog to p53. Like p53, both p63 and p73 bind to the 
canonical p53-responsive element, transactivate p53 target gene expression, 
and induce apoptosis when overexpressed (Review: Yang and McKeon, 2000). 
 
These findings suggest a role of Trps1 in the cell cycle control of mouse 
fibroblasts, in particular in the regulation of growth arrest and cell death, by 
means of transcriptional repression (direct or indirect) of transcription factors 
involved in important signaling pathways. The hypothesis that Trps1 may be 
implicated in apoptosis was raised by Chang et al. (2000;2002). The authors 
observed that physiological levels of androgens repressed the expression of 
GC79/TRPS1 mRNA in LNCaP-FGC (androgen-dependent human prostate 
cancer cells). Castration-induced androgen withdrawal in rat ventral prostate, 
used to induce apoptosis in the prostate, increased the expression of 
GC79/TRPS1 mRNA leading to the hypothesis that GC79/TRPS1 can be 
implicated in the process of apoptotic cell death in the rat ventral prostate.  
Moreover, TRPS1 interacts with the dynein light chain LC8a, which is able to 
strongly reduce the transcriptional repression activity of TRPS1 (Kaiser et al., 
2003a). LC8a interacts with Bim, a member of the Bcl-2 family, and is able to 
regulate its pro-apoptic activity (Puthalakath et al., 1999).  Apoptosis is 
probably the mechanism responsible for the death of mature hypertrophic 
chondrocytes during endochondral bone formation and deletion of the gene 
encoding Bcl-2, which is a cell-death inhibitor, leads to accelerated maturation 
of chondrocytes and shortening of long bones (Amling et al., 1997). 
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Furthermore, Bcl-2 regulates hair follicle apoptosis as well (Müller-Röver et al., 
1999). 
These results obtained in NIH3T3 cells indicate that Trps1 may play an 
important role in the cell cycle control. 
 
 
4.3.2  Microarray analysis of GATA Znf-deleted Trps1 mouse 
embryonic tissues 
 
So far, no further analysis of the differentially expressed genes in NIH3T3 cells 
was performed, because the study of the different tissues from the GATA Znf-
deleted Trps1 mice (Malik et al., 2002), provided by Dr. Ramesh Shivdasani 
(2.1.6) represented an enhanced model of study. In particular, the expression 
profiles of limbs and snouts of the Trps1 knockout mice have been analyzed, 
as these are the tissues usually affected by mutations in the TRPS1 gene in the 
human patients (see Results 3.4). 
 
The mice generated by Malik et al. (2002) are not Trps1-null mice. Like the 
TRPS type I patient described by Lüdecke et al. (2001) who carries the splice 
site mutation IVS6+1G>T, only one domain of the Trps1, the GATA-like Znf 
domain, is deleted in the mutant mice. RT-PCR analyses demonstrated the 
presence of stable GATA Znf-deleted Trps1 mRNA in both Trps1+/∆GATA-Znf   and 
Trps1∆GATA-Znf/∆GATA-Znf mice (data not shown). This could in part explain the low 
fold change (comprised between 1.5 and 2.6) in the expression values, 
detected comparing the expression profiles of limbs and snouts of wild type 
and mutant animals. So far, the only known function of TRPS1 is as repressor 
of GATA-mediated transcription. The Trps1 GATA Znf-knockout does probably 
not abrogate completely the function of the transcription factor, because it still 
contains eight of its nine Znfs and its NLS domain. Only the GATA-mediated 
repressional activity may be affected. If, for example, the six N-terminal Znfs 
control a pathway different and independent from the GATA-mediated, these 
pathways should not be affected. Moreover, it is not yet known whether TRPS1 
acts as repressor or as co-repressor. In the latter case, the reduced Trps1 
repressional function in the GATA Znf-deleted Trps1 knockout mice could be 
replaced by other still intact transcription factors.  
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Anyway, to discriminate between truly differentially expressed genes and false 
positives and to obtain a consistent confirmation of the microarray data, RNAs 
from limbs and snouts of additional wild type and mutant animals from several 
litters, at stage E11.5 (for the limbs) and E12.5 (for the snouts) of 
development, were analyzed by real-time PCR. 
In this way, also the limitations due to normal physiological variance in gene 
expression (even found in members of the same litter) and due to the process 
of sacrificing the animals or to different RNA preparations (Pritchard et al., 
2001) can be partially overridden. Therefore, the confirmation of the overall 
expression changes for about 50% of the 18 genes selected for the validation 
was a promising result for further experiments. Based on these considerations, 
it can be expected that of the total differentially expressed genes in the 
mutant mice, a similar percentage to that detected by real-time PCR will also 
be confirmed. 
 
Only 7.5% of the abnormally expressed genes were found to follow the same 
direction of expression in both Trps1+/∆GATA-Znf and in Trps1∆GATA-Znf/∆GATA-Znf mice. 
This finding was not unexpected. In fact, haploinsufficiency in mice does not 
seem to be as critical as in humans for the onset of genetic diseases. In 
addition to the heterozygous GATA Znf-deleted Trps1 mice, which have a 
milder phenotype than the TRPS patients, other examples of heterozygous 
mouse models for dominantly inherited diseases not affected as severely as 
the human patients are existing. The Ext1+/- embryos, for example, do not 
show the typical multiple exostoses of the long bones and deformities of legs, 
forearms and hands, usually present in patients with the autosomal dominant 
disorder human hereditary multiple exostosis type 1 (Lin et al., 2000). More, 
whereas the Msx1-/- mice show defective and thinner nail plates than those of 
the wild type littermates, the Msx1+/- mice are normal without the typical 
features of Witkop syndrome or TNS (tooth and nail syndrome), a dominant 
disorder characterized by nail dysplasia and missing teeth (Jumlongras et al., 
2001). On the other hand, haploinsufficiency of Sox9 (Bi et al., 2001) and 
Cbfa1/Runx2 (Otto et al., 1997) in heterozygous mice display the typical 
features of campomelic dysplasia (CD) and cleidocranial dysplasia (CCD) 
respectively. In the case of Trps1, the pathways controlled by Trps1 appear 
not be as concentration sensitive as in humans. 
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Since cDNA microarray analyses allow the identification of both direct and 
indirect downstream genes of a transcription factor, the largest part of the 
genes found to be differentially expressed in Trps1 mutant mice is probably a 
result of secondary events mediated by the directly induced or repressed 
transcriptional repressors and activators respectively, or a result of 
pathological processes. 
 
 
4.3.2.1 Downstream genes of Trps1 in embryonic limbs 
 
Using the Affymetrix arrays MOE430A, which contain about 22000 probe sets, 
323 and 226 differentially expressed gene were identified by comparing the 
expression profiles of wild type mouse embryonic limbs with those of 
Trps1+/∆GATA-Znf and Trps1∆GATA-Znf/∆GATA-Znf mouse embryonic limbs respectively 
(see Results 3.4.1). The very small range of fold change (between 1.5 and 
2.1) in the expression values obtained for the abnormally expressed genes 
may partially be due to the dilution of the GATA Znf-deleted Trps1 effects in 
the growth plates, where it is expected to exert its main regulatory function by 
surrounding tissues (muscle, skin etc.). Anyway, this finding did not prevent 
the identification of direct downstream genes.  
 
Different criteria were considered for the selection of twelve genes chosen for 
independent validation, since only few genes, which are known to act in the 
most important pathways involved in endochondral ossification, were present 
among the differentially expressed genes. Eng, Emp3 and Gadd45g were 
selected because they were downregulated both in the Trps1+/∆GATA-Znf and in 
the Trps1∆GATA-Znf/∆GATA-Znf mice. Extl2 is involved in biosynthesis of heparan 
sulfate. Hspg2 encodes the core protein of an important heparan sulfate 
proteoglycan, named perlecan, which is a major component of the basement 
membrane and has critical role in cartilage development. Wnt5b, Madh4, 
Hoxb8 and Dlx3 are expressed in epiphyseal growth plates and the gene 
products are involved in bone development. Traf6 plays an important role in 
the development of tooth number and shape [teeth anomalies such as 
malocclusion and supernumerary teeth have been reported for TRPS patients 
(Gorlin et al., 2001)]. Lamb1 is an important component of the basement 
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membrane. Laptm4b is the only gene to be upregulated in heterozygotes and 
homozygotes, in both examined tissues embryonic limbs and snouts. 
The real time PCR experiments confirmed the overall tendency of Hoxb8, 
Lamb1, Emp3, Laptm4b and Hspg2 values. The relative expression values of 
Eng and Gadd45g could be confirmed only in the Trps1∆GATA-Znf/∆GATA-Znf animals.  
As already mentioned, Trps1 might be involved in the regulation of cell cycle 
arrest and apoptosis (see 4.3.1). Gadd45g (growth arrest and DNA-damage-
inducible 45 gamma) is a member of a family of evolutionarily conserved, 
small, acidic, nuclear proteins, which have been implicated in terminal 
differentiation, growth suppression, and apoptosis. Gadd45 proteins are likely 
to cooperate in activation of S and G2/M checkpoints following exposure of cells 
to UV irradiation (Vairapandi et al., 2002). There are no reports about 
expression of Gadd45g in chondrocytes, but Northern blot analysis showed 
expression in skeletal muscle (Takekawa and Saito, 1998), which is present in 
the whole limb used to isolate the RNA for the microarray analyses.  
Taylor and Suter (1996) proposed that EMP3 is involved in cell proliferation 
and cell-cell interaction. Eng (endoglin) is a homodimeric membrane 
glycoprotein primarily associated with human vascular endothelium and it is a 
component of the transforming growth factor beta receptor complex. Endoglin 
is essential during angiogenesis (Li et al., 1999) and recent studies indicate 
that it promotes endothelial cell proliferation (Lebrin et al., 2004). It is not 
known whether they are expressed, for example, in chondrocytes or in hair 
follicles. Anyway, a disturbed chondrocyte proliferation in the growth plates is 
likely to be involved in TRPS skeletal pathogenesis, making these two genes 
interesting for further analyses. 
Noteworthy is the overexpression of Hoxb8 in the Trps1∆GATA-Znf/∆GATA-Znf mice. 
Hox proteins are transcription factors that control developmental pathways 
along the anteroposterior axis of vertebrates. This information is consistent 
with the high expression of Trps1 along the axial skeleton of E11.5-E12.5 
mouse embryos (Kunath et al., 2002). Ectopic expression of Hoxb8 was shown 
to cause, beside the duplication of the ZPA (zone of polarizing activity) in the 
forelimb, homeotic transformation of axial structures (Charité et al., 1994). 
Also the Trps1∆GATA-Znf/∆GATA-Znf mice display axial skeletal defects that are 
responsible for the lethal respiratory failure in newborns. Axial skeletal 
abnormalities, like kyphoscoliosis, have been described in Trps1+/∆GATA-Znf mice 
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and in some TRPS patients as well (Felman and Frias, 1977; Goodman et al., 
1981; Howell et al., 1986; Cope et al., 1986).  
The expression of two genes encoding widespread components of the 
basement membrane (BM), Lamb1 (one of the four different laminin beta 
chains, components of some of the laminin molecules) and Hspg2, was 
upregulated in the Trps1∆GATA-Znf/∆GATA-Znf and in the Trps1+/∆GATA-Znf mice, 
respectively. BMs are thin sheets of specialized extracellular matrix at the 
epithelial/mesenchymal interface of most tissues, whose components are able 
to regulate biological activities such as cell growth, differentiation, and 
migration, and to influence tissue development and repair (review: Erickson 
and Couchman, 2000). Perlecan and laminin are also present in the matrices of 
hyaline cartilage in the nasal septum, the articular surface of the bone and the 
growth plate of the developing bone (SundarRaj et al., 1995).  
Both proteins play crucial roles during early development events as 
demonstrated by loss-of-function mutations mouse models: Lamb1 is essential 
for BM integrity (Miner et al., 2004) and perlecan for cartilage and cephalic 
development (Arikawa-Hirasawa et al., 1999). These features make these 
genes interesting in correlation with TRPS. Moreover, the HSPG2 promoter 
contains nine GATA-consensus sequences (Iozzo et al., 1997) and 
consequently was selected for further functional studies, which demonstrate 
that HSPG2 is a direct target of the TRPS1 transcription factor (see 4.3.2.4 for 
comments). Similar studies were performed with LAPTM4b promoter region, 
which has two GATA-consensus sequences. TRPS1 was able to repress the 
promoter activity of this gene as well (see 4.3.2.3 for comments). 
It is not yet known whether Gadd45g, Emp3, Eng, Hoxb8 and Lamb1 are direct 
targets of Trps1 or downstream genes, whose abnormal expression derive 
from regulation of secondary transcription factors. Furthermore, many other 
differentially expressed genes deserve to be deeply analyzed in further 
experiments. These investigations will be performed in the next future. 
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4.3.2.2 Downstream genes of Trps1 in embryonic snouts 
 
Since rodents accurately reproduce human head development, gene targeting 
in mice has generated more than 90 loss-of-function mutants that show 
craniofacial malformations (review: Wilkie and Morris-Kay, 2001).  
However, some features of TRPS, like the thin upper lip, the bulbous tip of the 
nose and the protruding ears are difficult to find in the related TRPS mouse 
model, if present at all. On the contrary, other defects detected in the mouse 
snouts, like the abnormally arched palate in heterozygotes and the recessed 
chin in homozygotes are also found in patients with TRPS. Thus, the high level 
of expression of Trps1 during embryonic development in mouse snouts and the 
hair follicle defects present in the patients, as well as in the mice, make the 
snout an interesting model of study to understand the TRPS pathology (see 
Results 3.4.2). 
 
There are many genes worth more accurate investigations. For a start, six 
genes among the ~700 differentially expressed were selected for validation 
with real-time PCR, according to different criteria. Col2a1, whose product is a 
marker for the matrix of proliferating chondrocytes, is involved in many 
skeletal dysplasia known as type II collagenopathies (see introduction 1.1.1). 
Col9a1, if mutated, causes multiple epiphyseal dysplasia (see introduction 
1.1.1). Nov, which maps to 8q24.1 telomeric to TRPS1, is expressed in 
prehypertrophic and early hypertrophic chondrocytes. Fzd6 is involved in hair 
patterning. Prrx1, which is a homeobox gene, is required for early events of 
skeletogenesis in multiple lineages. Laptm4b is the only gene overexpressed in 
mouse limbs and snouts of both Trps1+/∆GATA-Znf and Trps1∆GATA-Znf/∆GATA-Znf mice. 
All genes followed the same trend of abnormal expression in both mutant 
genotypes.  
During this PhD work the overall tendency of change was confirmed for the 
three genes Nov, Fzd6 (only for the homozygotes) and Laptm4b. 
Nov (nephroblastoma overexpressed) is a member of the CCN family of genes 
[Connective tissue growth factor (CTGF), Cystein rich protein (Cyr61) and 
Nephroblastoma overexpressed gene (NOV)], which are known to participate 
in fundamental biological processes such as cell proliferation, attachment, 
migration, differentiation and angiogenesis. Nov provided the first example of 
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a CCN protein with negative regulatory properties (review: Perbal, 2001). Nov 
is expressed in differentiating growth plate chondrocytes and is negatively 
regulated by PTHrP (Yu et al., 2003). Previous immunocytochemistry studies 
performed on paraffin embedded chicken wing bud sections demonstrated the 
association of NOV with the ECM (Perbal, 1994). 
Fzd6 (frizzled6) is a member of a large family of integral membrane Wnt 
receptors. It is expressed in the skin and hair follicles and is important for cell 
polarity and controls hair polarity in mice (Guo et al., 2004). 
 
 
4.3.2.3 Laptm4b is the only gene upregulated in both Trps1+/∆GATA-
Znf and in Trps1∆GATA-Znf/∆GATA-Znf mice, in embryonic limbs and 
snouts 
 
The LAPTM4b promoter region, which carries two GATA-consensus sequences, 
was used to drive the cDNA luciferase in a reporter gene assay, showing that 
TRPS1 was able to directly reduce its transcriptional activity (see Results 
3.4.2.2).  
LAPTM4b is a novel gene, which encodes two isoforms of proteins with 
molecular masses 35-kDa and 24-kDa, designated as LAPTM4b-35 and 
LAPTM4b-24, translated from the first and second ATG in ORF (Shao et al., 
2003; Liu et al., 2004). Computer analyses showed that LAPTM4b is an 
integral membrane protein with four highly conserved hydrophobic 
transmembrane domains, forming two extracellular loops, a cytoplasmic loop 
and intracellular amino- and carboxyl tails. It is widely expressed in human 
tissues, mainly in heart, skeletal muscle, kidney and testis (Shao et al., 2003).  
LAPTM4b is upregulated in hepatocellular carcinoma (HCC) when compared 
with paired non cancerous liver (PNL) or normal liver tissues (NL) of the same 
patient. Notably, the expression level of LAPTM4b-35 was significantly related 
to the differentiation status of HCC tissues, higher in poorly differentiated 
HCCs than in moderately and well-differentiated HCCs. In addition, the ratio of 
LAPTM4b-35 to LAPTM4b-24 was remarkably higher in HCC than in PNL and 
NL. The authors suggest that LAPTM4b-24 may play an antagonistic role in cell 
survival and proliferation, and the equilibrium of LAPTM4b-35 and LAPTM4b-24 
in expression is involved in controlling cell survival/proliferation and 
   80
Discussion 
differentiation. Promoter activity studies in two HCC-related cell lines showed 
different levels of activity suggesting two different mechanisms regulating the 
expression of LAPTM4b in the two cell lines (Shao et al., 2003).  
LAPTM4B was not detected in human cervical carcinoma cell line HeLa (Liu et 
al., 2004), and infact its promoter did not show any activity in these cells in 
the reporter gene assay performed during this PhD work (see Results 3.4.2.2).  
 
Interestingly, the expression of LAPTM4B was also higher in highly metastatic 
cell lines including prostate carcinoma PC-3M androgen-independent cell line, 
and pulmonary giant cell carcinoma BE1 cell line (Liu et al., 2004). Since 
TRPS1 is higher expressed in androgen-dependent human prostate cancer cells 
(initial phase) than in androgen-independent human prostate cancer cells 
(next phase) (Chang et al., 2000), the reduction of the TRPS1 repressional 
activity on LAPTM4b could explain its overexpression in highly metastatic 
prostate carcinoma cells.  Moreover, LAPTM4b was reported to be involved in 
increased cell growth and proliferation rates, when transfected in NIH3T3 cell 
(He et al., 2003).  
These findings might indicate that the repressional activity of TRPS1 on 
LAPTM4b is important in the control of cell cycle. 
 
The fact that Laptm4b is overexpressed in both Trps1+/∆GATA-Znf and      
Trps1∆GATA-Znf/∆GATA-Znf mice confirmed the hypothesis of Malik et al. (2001) that 
the repressional activity of TRPS1, exerted here on LAPTM4b, depends on an 
intact GATA-Znf. Additional functional analyses are required to understand the 
possible role of LAPTM4b in the pathogenesis of the TRP Syndromes. It would 
be interesting to know the exact expression pattern, for example in cartilage 
during endochondral ossification or in hair follicle and to identify putative 
binding partners. Anyway, Laptm4b overexpression in both embryonic limbs 
and snouts implicate that the signaling pathway where Laptm4b acts depends 
in part on Trps1. 
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4.3.2.4        TRPS1 directly represses HSPG2 promoter activity 
 
It was demonstrated that HSPG2 is a direct target of TRPS1 (see Results 
3.4.1.2). 
HSPG2 maps to 1p36 and has 97 exons (Cohen et al., 1993).  It encodes the 
core protein of a large heparan sulfate proteoglycan, called perlecan, which is 
present in all native BMs. The core protein consists of five distinct domains 
(Cohen et al., 1993) and is post-translationally modified by two or three 
heparan sulfate (HS) chains at the N-terminus (Paulsson et al., 1987) and one 
choindroitin sulfate or HS chain at the C-terminus (Tapanadechopone et al., 
1999). The ~1.7 kb of the perlecan promoter analyzed with the reporter gene 
assay (see Results 3.4.1.2) have only a reduced transcriptional activity (Iozzo 
et al., 1997) and contain nine GATA motifs.  
Perlecan exerts many functions. Among other, it stabilizes matrix organization 
and cell-matrix interaction by binding other BM molecules (laminin, collagen IV 
and nidogen/entactin) (Hopf et al., 1999), ECM molecules (fibulin, fibronectin) 
(Brown et al., 1997) and cell surface receptors (integrin ß1 and α-
dystroglycan) (Brown et al., 1997; Talts et al., 1999). It binds and stores 
growth factors like FGF and platelet-derived growth factors (Knox et al., 2002; 
Mongiat et al., 2000; Gohring et al., 1998). It possesses angiogenic and 
growth-promoting attitudes by acting as a coreceptor for basic fibroblast 
growth factor, FGF2 (Aviezer et al., 1994).  
 
The HSPG2 gene is already expressed during the 2-4 cell stage of mouse 
development (Dziadek et al., 1985) and disruptions of both the Drosophila 
(trol) (Datta and Kankel, 1992) and C. elegans (Unc-52) (Rogalski et al., 
1993; Rogalski et al., 2001) orthologues result in severe developmental 
defects in eye and muscle respectively (Datta and Kankel, 1992; Rogalski et 
al., 1995). 
Important to understand the correlation with TRPS pathogenesis, is the strong 
Hspg2 expression, in addition to the BMs, in matrix of cartilage (especially in 
the pericellular matrix, surrounding the periphery of chondrocytes) undergoing 
endochondral ossification in the growth plate, mainly in the prehypertrophic 
and hypertrophic zones (Arikawa-Hirasawa et al., 1999). It is also expressed in 
adult hyaline cartilage, including the articular cartilage (SundarRaj et al., 
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1995). Interestingly, French et al. (1999) probed frozen sections from mouse 
embryos with a specific mouse perlecan antibody and showed that at E12.5 
perlecan protein was low in cartilage primordial (where Trps1 is very high 
expressed), but it accumulated as development progressed through E13.5 and 
E14.5 (when Trps1 expression is reduced). They also demonstrated that 
perlecan, in the presence of its constituent HS chains, maintained and strongly 
potentiated chondrogenic differentiation in vitro.   
 
Two Hspg2-null mouse models (Arikawa-Hirasawa et al., 1999; Costell et al., 
1999) and a HS chain-deficient perlecan mouse model have been generated 
(Rossi et al., 2003). Some of the perlecan-null embryos die during an early 
crisis (E10.5-E12.5) because of severe defects in cephalic or hearth 
development, probably due to altered basement membrane formation in the 
absence of perlecan. The remaining mutants survive to the perinatal period but 
develop severe brain and skeletal defects, like short long bones and 
craniofacial defects. The perlecan-null mice show severe defects in the growth 
plates (reduced chondrocytes proliferation and differentiation) during the 
endochondral ossification. No significant cartilage abnormalities were found 
prior to E13.5 (when the endochondral ossification starts) and afterward 
matrix disruption becomes evident and progressively severe. These findings 
suggest an essential role of perlecan for cartilage development, even if its 
precise role is not yet known. Mutant mice whose fibroblasts secrete perlecan 
that mainly carries chondroitin sulfate and only a small amount of HS are 
viable and fertile, but have defective eyes (like Drosophila perlecan-null  
mutants, see above).  The lenses of the homozygous mice degenerate within 
three weeks after birth, because of an altered structure of the lens capsule, 
which is a specialized, very thick BM where perlecan is normally found. The 
fine structure of the cartilage in the affected mice has not been examined. 
 
Similarities of the skeletal abnormalities of perlecan-null embryos led to the 
identification of a human disorder, Dyssegmental dysplasia, Silverman-
Handmaker type, which is a lethal autosomal recessive skeletal dysplasia 
characterized by anisospondyly and micromelia. The fibroblasts of the three 
patients identified for perlecan mutations were not able to secrete the 
truncated perlecan proteins (Arikawa-Hirasawa et al., 2001). Mutations in 
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HSPG2 are also involved in the rare recessive disorder Schwartz-Jampel 
syndrome, which is a unique combination of myotonia and chondrodysplasia. 
In this case, different forms of perlecan are secreted to the ECM and are 
partially functional (Nicole et al., 2000; Arikawa-Hirasawa et al., 2002). 
 
 
4.3.2.5 Is Hspg2 overexpression in the growth plate responsible 
for disturbed cell-matrix interaction in the chondrocytes of 
TRPS patients? 
 
According to the microarray data, Hspg2 is upregulated only in the embryonic 
limbs of mutants but not in embryonic snouts, albeit it is expressed. This could 
implicate that the overexpression of Hspg2 is involved only in the pathways 
which, if disturbed by mutated Trps1, lead to the skeletal defects but not the 
facial features present in TRPS patients.  
 
The typical skeletal defects of the TRPS patients, like the short stature and the 
cone-shaped epiphysis are due to a premature closure of the growth plates.  
In normal growth plates, perlecan binds many molecules and many growth 
factors, which are involved in cartilage development, stimulates angiogenesis 
and induces chondrocyte differentiation. The high level of HSPG2 expression in 
the growth plates is likely to change the composition of the ECM in the growth 
plates. Regional differences in the cartilage matrix composition probably are 
functionally critical in hyaline cartilage of the growth plate. During 
endochondral ossification, the matrix is likely to influence the continuous 
behavioral and metabolic changes in the chondrocytes. So maybe the altered 
cell-matrix interactions due to a higher level of perlecan in the cartilage matrix 
could be responsible, at least in part, for the impaired differentiation of 
chondrocytes in the growth plates of TRPS patients. Moreover, perlecan may 
modulate signaling pathways regulating chondrocyte proliferation and 
hypertrophy by sequestering important ligands.  
Further functional analyses are required to corroborate this hypothesis. For 
example, it would be important to know whether HSPG2 is really 
overexpressed in chondrocytes of TRPS patients. If this is the case, Hspg2 
overexpression studies in mice under the control of a chondrocyte specific 
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promoter would help to understand in detail the defects supposed to be caused 
by disturbed cell-matrix interactions in the growth plate. 
 
 
4.3.2.6  Does HSPG2 overexpression contribute to the onset of 
osteoarthritis in TRPS patients? 
 
An important complication of TRPS is a progressive degenerative arthritis 
(Felman and Frias, 1977; Cope et al., 1986). Osteoarthritis (OA) is a disorder 
of the joints, characterized by progressive deterioration of the articular 
cartilage. Central point in the pathogenesis is a disturbed cell-matrix 
relationship. Recently, Tesche and Miosge (2004) found an increased level of 
perlecan protein in the area adjacent to the main cartilage defect in the knee 
joints of ten patients suffering from OA. In particular, more perlecan was 
produced by the elongated type 2 chondrocytes, mainly found in the deep 
zones of articular chondrocyte of the areas adjacent to the main defect, which 
are the cells principally responsible for the regeneration processes of cartilage 
matrix (Bock et al., 2001). In normal cartilage, perlecan interacts with other 
adhesive extracellular macromolecules to stabilize and produce the 
compressed matrix and to enable the adhesion of chondrocytes to their own 
substrate. Therefore, the authors suggested that the higher level of perlecan 
could be an attempt on the part of the cartilage tissue to stabilize and protect 
the remaining matrix of late-stage osteoarthritic cartilage from further 
destruction.  
 
In contrast, the data obtained in this PhD work would suggest that the high 
level of perlecan present in the articular cartilage could be the cause for the 
onset of OA, at least in the TRPS patients, and not a way to protect the matrix. 
If TRPS1 is mutated, the repression of HSPG2 expression by TRPS1 may not 
normally take place and thus perlecan accumulates, among other, in the 
articular cartilage, causing disturbances in the cell-matrix interactions, which 
could contribute to the origin of OA. 
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5.  ABSTRACT 
 
Mutations in the TRPS1 gene cause the tricho-rhino-phalangeal-syndrome 
(TRPS) type I and III, which are characterized by craniofacial and skeletal 
defects. The gene encodes a transcription factor that has a GATA-binding zinc 
finger and represses GATA-regulated gene expression.  
Mutation analysis of TRPS type I patients helped to identify the nuclear 
localization signal of TRPS1. 
To study the pathogenesis of TRPS, a TRPS1 transgenic mouse model 
expressing a potentially dominant negative TRPS1 allele in chondrocytes was 
generated. However, the mice expressed the transgene at a low rate only, and 
even adult mice did not show the typical brachydactyly or growth retardation. 
For identifying genes that are directly and indirectly regulated by TRPS1 two 
different strategies were followed.  
(I) A combination of RNA interference-mediated Trps1 silencing and cDNA 
microarray analysis allowed the identification of putative downstream genes of 
Trps1 in mouse NIH3T3 cells. Several genes overexpressed in cells where 
Trps1 was silenced are involved in the control of cell cycle progression or 
apoptosis. 
(II) Expression profiles of normal mouse embryonic limbs and snouts were 
compared with embryonic limbs and snouts of mice carrying a targeted 
deletion of the Trps1 GATA zinc finger. Several downstream genes implicated 
in cell cycle control, signal transduction, cell organization and transcription 
regulation were identified, and their relative expression values were verified by 
real-time PCR. Luciferase reporter-gene assays allowed the identification of the 
first potential TRPS1 target genes, LAPTM4b and HSPG2. Both promoters 
contain GATA motifs and can be repressed by TRPS1. LAPTM4b (lysosomal-
associated transmembrane protein 4b) is probably involved in cell cycle 
control. HSPG2 codes for perlecan, the major heparan sulfate proteoglycan in 
the cartilage matrix. 
These findings suggest a role for Trps1 in the regulation of cell cycle control 
and in the maintenance of cell-matrix interactions. 
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6. APPENDIX 
 
TRPS1 TRANSGENIC MICE   
primer sequences 5’-3’  
(f):forward   (r):reverse 
 
- to insert the specific A2701C mutation in the human TRPS1 cDNA by in vitro 
site-directed mutagenesis (in bold is indicated the location of the mutation) 
 
GATA5     GCCTGCCCACAAAGACCTCTCTC 
GATA3     GAGAGAGGTCTTTGTGGGCAGGC 
 
-  to insert the human TRPS1 cDNA in the pNASSßCol2a1 (underlined are the 
EcoRI site in linker 1 and the BglII site in linker 2) 
 
linker 1  (f)   GGCCGCATGAGATCTGCAGATATCAG 
linker 2  (r)   CGTACTCTAGACGTCTATAGTCGCCGG 
 
- probe for Southern blot analysis 
 
Col2a1 promoter (f) TCCTAGGGCCTCCTGCATGAGG 
TRPS1 exon 3 (r) TTGAAGCCAGCCTTCTCACT 
 
- to asses the transgene expression  
 
1^PCR strategy 
Col2a1 promoter (f)  TCCTAGGGCCTCCTGCATGAGG 
TRPS1 exon 3 (r)   TTGAAGCCAGCCTTCTCACT 
 
2^PCR strategy 
exon 5  (f)   TTGGAGAGGGGCAGACATCC 
exon 7  (r)       CCTGAGGACTTTTTATCTGAATGT 
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LUCIFERASE REPORTER-GENE ASSAYS  
primer sequences 5’-3’ 
 
- to amplify the 1711 bp HSPG2 promoter region (GenBank accession n. 
L81166), then inserted into the reporter plasmid (pGL3-Control) for the 
luciferase reporter-gene assay. The parentheses indicate the location into 
the promoter region. 
 
HSPG2_forward    CCTGGTGTACTCTCCCCTCA   (nt 125-144) 
HSPG2_reverse    GGACGCCTTTTCACATAG   (nt 1819-1836) 
 
 
-  to amplify the 1532 LAPTM4b promoter region (GenBank accession n. 
AY057051F), then inserted into the reporter plasmid (pGL3-basic) for the 
luciferase reporter-gene assay. The parentheses indicate the location into 
the promoter region. 
 
LAPTM4b_forward    GCTCCAGGTGGAAGAGTGTGC  (nt 1-21) 
LAPTM4b_reverse  GGACTTGGCCATGTGACCCG  (nt 1513-1532) 
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